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Abstract 
 
 
Cancer is a worldwide cause of concern. The incidence, prevalence and death rates of 
this disease have not yet been considerably attenuated over the years. Novel and innova-
tive treatments are emerging as a result of the increasing knowledge on the biology of 
cancer. Cancer cells seem to adapt and evolve new evasive pathways along with the pro-
gression of cancer therapy. Multi-drug resistance is a characteristic acquired by certain 
types of cancer, such has lung cancer, that severely decreases the efficiency of chemo-
therapy. One of the approaches explored to mitigate this issue is the implementation of 
combined drug therapy. Natural products have been long-term “allies” of mankind in the 
treatment of disease. In the last decades the marine environment has gained interest as a 
plentiful source of natural products with multiple biotechnological applications. Cancer 
treatment is one of the fields that is benefiting from marine-derived products. Indeed, the 
search for new drugs with unique mechanisms of action is of clear interest, and the ma-
rine environment, which is still largely untapped, may provide answers to many of the 
pharmaceutical requests of today.  
In our study the in vitro anticancer activity of crude ethyl acetate extracts of marine-
derived fungi Neosartorya tsunodae KUFC 9213 (E1) and Neosartorya laciniosa KUFC 
7896 (E2) and soil fungus Neosartorya fischeri KUFC 6344 (E3) were tested on a panel of 
seven human cancer cell lines (HepG2, HCT116, HT29, A549, A375, MCF-7 and U251). 
The in vitro anticancer activity of these extracts was assessed by several forms, in particu-
lar, short-term proliferative activity was assessed by an MTT assay, DNA damage was 
evaluated by an alkaline comet assay, effect on long-term proliferative activity was evalu-
ated by a clonogenic assay and cell death was measured by quantification of cell exhibit-
ing nuclear condensation and observation of morphological alterations. Extract E2 
demonstrated a clear in vitro anticancer effect by decreasing the clonogenic potential and 
increasing the induction of nuclear condensation in HCT116, A375, MCF7 and HT29 cells. 
Extract E3 demonstrated similar effects in MCF7 and HCT116 cells. The induction of DNA 
damage was observed in some cell lines. These results suggest that extracts E2 and E3 
possess an in vitro anticancer effect by inhibiting proliferation and inducing cell death in 
human colon carcinoma, breast adenocarcinoma and malignant melanoma cells, validat-
ing the interest for the identification of compounds isolated from these extracts in further 
studies. 
  iv 
The second phase of this work intended to evaluate the enhancement of the in vitro an-
ticancer activity of doxorubicin while in combination with the crude ethyl extracts of seven 
marine and soil-derived fungi, namely, Neosartorya tsunodae KUFC 9213 (E1), Neosar-
torya laciniosa KUFC 7896 (E2), Neosartorya fischeri KUFC 6344 (E3), Aspergillus sim-
ilanensis KUFA 0013 (E4), Neosartorya paulistensis KUFC 7894 (E5), Talaromyces 
trachsypermus KUFC 0021 (E6) and Neosartorya siamensis KUFA 0017 (E7) in the same 
panel of seven cancer cell lines. Eight compounds isolated from Neosartorya siamensis 
KUFA 0017 (E7), namely, 2,4-dihydroxy-3-methylacetophenon (C1), nortryptoquivaline 
(C2), chevalone C (C3), tryptoquivaline H (C4), fiscalin A (C5), epi-fiscalin C (C6), epi-
neofiscalin A (C7) and epi-fiscalin A (C8) were tested in combination with doxorubicin and 
cell viability was assessed in A549 lung cancer cell line. Extracts E1, E2 and E7 in combi-
nation with doxorubicin demonstrated a significantly enhanced effect in A549 cells, in 
comparison to the sole use of doxorubicin. A significant increase in DNA damage and 
nuclear condensation was also observed. Due to the effect demonstrated by extract E7 in 
combination with doxorubicin, eight compounds of this extract were tested in different 
combinatorial regimens in A549 cell line. All the isolated compounds (except C1) in com-
bination with doxorubicin potentiate the cytotoxic effect of the latter drug. Compounds C2, 
C5 and C7 in combination with doxorubicin demonstrated a greater effect in the decrease 
of cell viability when compared with extract E7 in combination with doxorubicin. Our data 
demonstrated the potential in enhancing (at least in vitro) the anticancer effect of doxoru-
bicin by the use of marine-derived fungi extracts and compounds.  
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Resumo 
 
O cancro é uma preocupação que atinge a escala mundial. A incidência, prevalência e 
taxa de mortalidade desta doença não tem atenuado ao longo dos anos. Alguns trata-
mentos inovadores têm emergido como resultado do crescente conhecimento da biologia 
do cancro. Contudo, as células cancerígenas adaptam-se e desenvolvem novos meca-
nismos de evasão ao acompanhar a progressão do tratamento. A resistência a múltiplas 
drogas é uma característica verifica em certos tipos de cancro, nomeadamente o cancro 
do pulmão, e que diminui drasticamente a eficiência e resposta à quimioterapia. Uma das 
abordagens adoptadas para a mitigação deste problema é a implementação de terapias 
com combinação de drogas. Os produtos naturais são “aliados” ancestrais da humanida-
de no tratamento de doenças. Nas últimas décadas, o ambiente marinho tem sido alvo de 
grande interesse como uma fonte abundante de produtos naturais com múltiplas aplica-
ções biotecnológicas. Inclusivamente, o tratamento do cancro tem sido uma das áreas 
beneficiadas por novos produtos de origem marinha. Torna-se assim evidente que a pro-
cura de novas drogas com mecanismos de acção únicos é de extrema relevância, e que 
o ambiente marinho, ainda vastamente inexplorado, pode providenciar respostas às ne-
cessidades farmacêuticas actuais.  
Neste estudo, a actividade anticarcinogénica in vitro de extractos de acetato de etilo de 
fungos de origem marinha, nomeadamente, Neosartorya tsunodae KUFC 9213 (E1) e 
Neosartorya laciniosa KUFC 7896 (E7) e do fungo de solo Neosartorya fischeri KUFC 
6344 (E2), foi avaliada num painel de sete linhas celulares (HepG2, HCT116, HT29, 
A549, A375, MCF-7 e U251). A actividade anticarcinogénica in vitro destes extractos foi 
avaliada de várias formas, nomeadamente, através da avaliação de inibição de prolifera-
ção celular a curto prazo pelo ensaio de MTT, da observação de indução de danos no 
DNA através do ensaio cometa, da inibição da proliferação celular a longo prazo, através 
do ensaio clonogénico, e da avaliação da indução de morte celular pela quantificação de 
condensação nuclear e por observação de alterações morfológicas. O extracto E7 evi-
denciou um claro efeito anticarcinogénico in vitro ao diminuir o potencial clonogénico das 
células, bem como ao aumentar a indução de condensação nuclear em células HCT116, 
A375, MCF7 e HT29. O extracto E2 demonstrou efeitos semelhantes em células MCF7 e 
HCT116. A indução de danos no DNA foi observada em algumas linhas celulares. Estes 
resultados sugerem que os extractos E7 e E2 possuem actividade anticarcinogénica in 
vitro ao inibir a proliferação e ao induzir a morte celular em células de carcinoma do có-
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lon, adenocarcinoma da mama e melanoma maligno, validando assim o interesse na 
identificação de compostos isolados destes extractos em estudos futuros. 
A segunda fase deste estudo pretendeu avaliar a potenciação do efeito anticarcinogé-
nico in vitro da doxorrubicina quando combinada com os extractos de acetato de etilo 
obtidos de sete fungos marinho e um fungo de solo, nomeadamente, Neosartorya tsuno-
dae KUFC 9213 (E1), Neosartorya laciniosa KUFC 7896 (E2), Neosartorya fischeri KUFC 
6344 (E3), Aspergillus similanensis KUFA 0013 (E4), Neosartorya paulistensis KUFC 
7894 (E5), Talaromyces trachsypermus KUFC 0021 (E6) e Neosartorya siamensis KUFA 
0017 (E7) no mesmo painel de sete linhas celulares. Oito compostos isolados do fungo 
Neosartorya siamensis (E7), nomeadamente, 2,4-dihydroxy-3-methylacetophenon (C1), 
nortryptoquivaline (C2), chevalone C (C3), tryptoquivaline H (C4), fiscalin A (C5), epi-
fiscalin C (C6), epi-neofiscalin A (C7) e epi-fiscalin A (C8) foram testados em combinação 
com doxorubicina na linha celular de pulmão A549. Os extractos E1, E2 e E7, quando 
combinados com doxorrubicina, demonstraram um efeito significativamente mais potente 
em células A549, em comparação com o uso exclusivo da doxorrubicina. Foi também 
observado um aumento significativo de indução de danos no DNA e de condensação 
nuclear. Face à magnitude do efeito do extracto E7 combinado com doxorrubicina, foram 
testados oito compostos isolados deste extracto em vários emparelhamentos combinató-
rios com doxorrubicina, na linha celular A549. Quando combinados com aquele fármaco, 
todos os compostos isolados, à excepção do composto C1, demonstraram um maior de-
créscimo de viabilidade celular em comparação ao uso de extracto E7 com doxorrubicina. 
Estes resultados demonstraram, de forma inequívoca, a potencialidade de se utilizarem 
extratos e compostos de fungos de origem marinha para potenciar (pelo menos in vitro) o 
efeito anticarcinogénico da doxorrubicina. 
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Preface 
 
This work was developed in the course of the MARBIOTECH project in the Interdisci-
plinary Centre of Marine and Environmental Research (CIIMAR), of the University of Por-
to, which intends to obtain and evaluate different applications for the bioactivity of marine-
derived products. With this work, our contribution to this project was by assessing the in 
vitro anticancer activity of marine and soil-derived fungi extracts and compounds. 
In particular, the aim of this  study was to assess the in vitro anticancer activity — by 
evaluating the anti-proliferative activity, clonogenic potential, DNA damage and induction 
of nuclear condensation — of marine and soil-derived fungi extracts and compounds. Ad-
ditionally the potentiation of the in vitro anticancer activity of doxorubicin was evaluated by 
using combinatorial regimens of extracts and compounds in combination with doxorubicin.  
This thesis is presented over four chapters. Chapter 1 contains an introduction to can-
cer where epidemiologic data, cellular and molecular traits (with special focus in the biolo-
gy of lung cancer), therapeutic procedures for lung cancer are approached. Aspects of 
natural products, pharmaceutical applications of marine-derived drugs and a view over 
drug screening are equally presented. Chapter 2 includes an original manuscript submit-
ted to an international peer-reviewed journal, while Chapter 3 illustrates an original manu-
script to be submitted to an international peer-reviewed journal. Chapter 4 presents the 
global conclusions and introduces key future perspectives. The appendix includes a com-
prehensive presentation of the experimental protocols used over this thesis.  
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1. Introduction 
1.1.  Perspectives on human health and natural products 
The use of crude or more refined products from nature in order to acquire health bene-
fits is an ancient human habit, however, the consumption of many of these products has 
been scientifically proven to offer chemoprevention/protection for several human diseas-
es. Cancer is frequently embraced by society as a modern disease due to its increasing 
prevalence among human populations; in fact, cancer has accompanied human civiliza-
tions throughout time. Some of the earliest records of cancer as an illness dates back to 
3000 B.C. in Egypt, where the tumors were surgically removed and the disease was re-
ported as not possessing a definitive treatment (Sudhakar, 2009). The use of natural 
products with the intent to treat or prevent, dates back from the 12th century among Asian 
populations (Cai, Luo, et al., 2004). Plants were the initial target for a deeper search of 
bioactive compounds, due to their abundance, easy maintenance and propagation, and by 
the already demonstrated benefits among populations who actively consumed certain 
plant species as a cultural habit. The effective use of plants as a medicinal tool relies upon 
the plant’s production of secondary metabolites, which serve not only as the plant’s self-
defense mechanism, but also have the propensity to promote health improvements when 
included in the human diet (Briskin, 2000). Several of these products may possess mole-
cules with several biological activities, such as anti-oxidant, anti-inflammatory and anti-
proliferative potential, which could contribute for cancer prevention and treatment (Rathee, 
Holt, et al., 2009; Thomson and Ali, 2003). Consequently, the search for bioactive com-
pounds in nature has been widely validated by the number of drugs integrating the phar-
maceutical industry. Many of these drugs were discovered by inspiration or origin in na-
ture’s portfolio, which is particularly true for cancer treatment: from 1983 to 1994 about 
60% of FDA approved drugs had its origin in nature, either by plants, microorganisms or 
marine organisms (Newman, Cragg, et al., 2003). Since the 1960s, the effort to obtain 
drugs was focused towards the ocean, and by the mid-1980s around 2500 new metabo-
lites were reported (Cragg and Newman, 2013). This came to prove the enormous poten-
tial in the search of novel bioactive compounds from marine-derived sources.  
Considering the ocean as a rather generous source of products with high potential for 
medicinal application which could very well break even with land-derived products not only 
due its dimension, but also because marine organisms have faced millions of years of 
evolution and selective pressure. Therefore, they must possess diverse and competent 
chemical machinery that enables their survival in the harsh and constantly changing con-
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ditions of the marine environment (Boopathy and Kathiresan, 2010). The chemical portfo-
lio of marine organisms may find its most seamless and complex functionality amongst 
symbiotic organisms, since symbiotic organisms have been found to interact and aid each 
other using unique chemical output. Such products hold great potential, in particular due 
to the possibility of discovering novel chemical structures with biotechnological applicabil-
ity, namely for cancer treatment (Webster and Taylor, 2012).  
Chemotherapeutic agents for cancer therapy have been in clinical use for about half a 
century, and although some have proven efficiency in some type of cancers, in others, 
such as lung cancer, chemotherapy has not yet been able to overcome its puzzling biolo-
gy (Shanker, Willcutts, et al., 2010). The efficiency of a drug relies upon its ability to in-
duce cytotoxicity or/and cytostatic effect among the tumor cells (Hickman, 1992; Villasana, 
Ochoa, et al., 2010). Highly specific drugs are especially desirable, considering that alt-
hough it is critical to damage and limit cancer cells, it is also important to avoid the same 
effects on normal cells. A cytotoxic effect is often achieved by activating a cell death 
mechanism. This event can result from drug induction of apoptotic molecular pathways, 
which are often mutated in cancer cells (Greenblatt, Bennett, et al., 1994). The importance 
of drug-induced apoptosis is easily demonstrated, if one considers that around 80% of the 
currently used chemotherapy drugs function by activating a pro-apoptotic mechanism 
(Balde, Andolfi, et al., 2010).  
Most types of cancer become drug resistant during the administration of chemothera-
peutic agents to patients (Gottesman, 2002). Lung cancer is a classic example of a cancer 
with ample drug resistance mechanisms; this is in fact portrayed in the high prevalence 
and poor treatment prognosis, which is translated into a high mortality rate (Jemal, Bray, 
et al., 2011; Shanker, Willcutts, et al., 2010). One of the approaches that is commonly 
enforced to minimize drug resistance is the implementation of drug combination therapies, 
in order to explore multi-target mechanisms within the cancer cell (Belani, Choy, et al., 
2005).  
Finding new natural bioactive drugs requires the evaluation of the drug by means of a 
screening, where several characteristics of these new drugs are evaluated (Shoemaker, 
Scudiero, et al., 2002). Once the drug’s bioactivity is assessed, illations may be made as 
to whether the drug can be considered as a valid candidate to be combined with other 
drugs, thus hopefully resulting in the overall enhancement of bioactivity in relation to the 
use of both drugs alone (Zhang, Teruya, et al., 2013).  
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1.2.  Cancer demographics 
The burden of cancer is a matter that involves personal, social and governmental 
spheres. The concept of cancer has reached our daily living as a subject of present and 
future concern, and it certainly represents the face of an unexpected, sudden and a pain-
ful death. Environmental factors, aging, life-style and familiar history are major contribu-
tions towards the incidence, prevalence and mortality of cancer. Cancer is a global lead-
ing cause of mortality, being the first cause of fatal diseases in more developed countries, 
and the second in the less developed countries (Jemal, Bray, et al., 2011).  
 
1.2.1.  Current trends in cancer incidence 
A global estimate in 2012, estimated that 8.2 million people died of cancer, accompa-
nied by the appearance of 14.1 million new cases (Ferlay, Soerjomataram, et al., 2014). In 
contrast, in 2008 there was an estimation of 7.6 million deaths (64% in developing coun-
tries), and 12.7 million new cases (56% in developing countries) (Jemal, Bray, et al., 
2011). Even more markedly, estimates of the year 2000 suggested that 10.1 million of 
new cases and 6.2 million deaths had occurred that very year; this represented an in-
crease of 20% in both parameters, in comparison with the estimations for the year of 1990 
(Parkin, 2001). An interpretative analysis of these two periods must consider the high 
global population that occurred between these years. The lack of proper and well imple-
mented diagnosis methods alongside the patient’s difficulty to access efficient treatment 
may explain these high mortality rates in underdeveloped regions, even though the inci-
dence of the disease is less prevalent (Jemal, Bray, et al., 2011).  Projections for 2020 
estimate a total of 15.4 million new cases and 10.1 million deaths, and by 2050, an esti-
mate of 23.8 million new cases and 16 million deaths related to cancer (Parkin, 2001). 
 
1.2.2.  Insights in lung cancer incidence 
On a global scale, lung cancer is the most common type of cancer. Lung cancer has 
consistently increased every year, and represents 12.3% of all cancers with a total of 52% 
of these cases accounting for developed countries (Parkin, Bray, et al., 2001). In terms of 
gender, males are the most affected, accounting for 75% of all cases. In fact, this is the 
most recurrent type of cancer for the gender, and the third for females (data correspond-
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ent to the year 2000) (Parkin, 2001; Parkin, Bray, et al., 2001). Smoking habits are the 
predominant risk factor that dictates the possibility to develop the disease, in fact, 80% of 
lung cancers are recurrent in men and 50% in women with smoking habits (Jemal, Center, 
et al., 2010; Parkin, 2001). The increase of an individual’s smoking habits (e.g. passive 
smoking, amount of smoke inhaled and early age initiation) positively increases the prob-
ability to manifest the disease. Countries with a long lasting cultural habit of smoking are 
now more affected by this disease, possibly as a result of more exposure time and quanti-
tative contact with tobacco associated carcinogenic agents (Parkin et al., 2001). Familiar 
history, prior respiratory diseases and exposure to environmental pollutants, such as or-
ganic chemicals, radiation, asbestos, metals, chronic dust exposure, coal smoke, and 
other forms of air pollutants are also relevant factors for the development of lung cancer 
(Brenner, McLaughlin, et al., 2011; Spitz, Hong,  et al., 2007). The individual’s gene pool 
is quite relevant, since 17% of lung cancer cases are related with homozygous deletion on 
GSTM1 locus, a member of glutathione S-transferases (GST) family that act as detoxifier 
enzymes that inhibit the formation of DNA adducts, such as smoking-related DNA adducts 
in lung tissues (McWilliams, Sanderson, et al., 1995).  
Lung cancer histology characterizes the condition in two variants, i.e. the non-small cell 
lung and the small cell lung cancers. The first morphological type originates from bronchial 
epithelial-cell precursors and comprises large cell carcinoma, adenocarcinoma, squamous 
cell carcinoma and bronchioalveolar cell carcinoma, all of which account to 85% of lung 
cancer cases. Small cell lung cancer arises from neuroendocrine cell precursors (Marshall 
and Christiani, 2013; Ramalingam, Owonikoko, et al., 2011). 
 
1.3. Biology of cancer 
Carcinogenesis is not simply defined as a random growth process of an undifferentiat-
ed mass of cells. In fact, carcinogenic cells dominate and quite efficiently alter the firmly 
established cell cycle pathway associated to normal cells; cancer cells manipulate their 
surrounding microenvironment in their own advantage and ultimately avoid their host’s 
self-defense mechanisms. These cells proclaim their own space and nutrients, as oppos-
ing to normal cells. Cancer cells are relentless in their progression and are self-invaders 
that control their own course (DeBerardinis, Lum, et al., 2008).  
In 2011, and despite the histological origin and functional differences among the differ-
ent cancer cell types, common hallmarks were attributed to cancer: sustaining proliferative 
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signaling, evading growth suppressors, resisting cell death, enabling replicative immortali-
ty, inducing angiogenesis, activating invasion and metastasis, deregulating cellular ener-
getics, avoiding immune destruction, genome instability and mutation and tumor-
promoting inflammation. These biological characteristics conjointly promote the tumor-
igenic and carcinogenic process (Hanahan and Weinberg, 2011). 
 
1.3.1. Biology of lung cancer 
The detection and identification of lung cancer has made great advances through mo-
lecular and genetic identification tools (Cortes-Funes, 2002). Consequently, a more com-
plex and elucidated mapping of this disease’s biology is now known, in comparison to an 
entirely morphologic based analysis. Divisions based exclusively on histological criteria 
disregard most of the crucial molecular traits of the disease. Moreover, the discrepancy 
which is often observed in the efficiency of treatment amongst patients presenting the 
same histological cancer type is a call for the further exploration of vital information which 
may be found beyond morphology (Manegold, 2001; Ramalihngman, Owonikoko, et al., 
2011).  
At the moment, it is possible to establish a net of genetically identical traits in normal 
lung cells that, if present, may increase the risk of evolution towards malignancy. A region 
in the chromosome 15 contains the nicotinic acetylcholine receptor genes, which are 
thought to be involved in tobacco smoking dependence, and therefore implicated in the 
lung cancer mechanism (Thorgeirsson, Geller, et al., 2008). Some of the most common 
molecular abnormalities in lung cancer are mutations in EGFR, TP53 and KRAS genes 
(Marshall and Christiani, 2013). The epidermal growth factor receptor (EGFR) belongs to 
a family of cell-surface receptors, with the function of activating cellular mechanisms me-
diated through extra-cellular factors. These factors could ultimately lead to the regulation 
of such functions, as for example apoptosis and angiogenesis (Krause and Van Etten, 
2005). The EGFR gene is mutated in a considerable percentage of NSCLC carriers (e.g., 
40% of East Asian carriers), which motivated drug trials using EGFR inhibitors, which lead 
to the conclusion that carcinogenic cells promptly acquire resistance to these inhibitors 
(Kobayashi, Boggon et al., 2005).  
Transcriptor factor p53 (TP53) is a central tumor suppressor gene. It acts in cell cycle 
arrest, allowing the evaluation of internal damages (e.g. DNA damage) which will deter-
mine if the cell proceeds further in the cell cycle or if it is forwarded to initiate cell death 
(Li, Kon, et al., 2012). TP53 gene is frequently mutated in lung cancer. The prevalence of 
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this mutation is dependent on the histological type of cancer.  In one case study, it was 
found to be more frequent in cell squamous carcinoma (35%) when compared with ade-
nocarcinoma (20%), yet the overall expression of this gene along the chain of the tumor-
igenesis events remains in some points poorly comprehended (Gao, Mady, et al., 2003). 
The RAS gene family is composed by three proto-oncogenes (KRAS, 
HRAS, or NRAS). These genes have an active role in the maintenance of the proliferation, 
apoptosis, metastasis and immune response (Pylayeva-Gupta, Grabocka, et al., 2011). 
Mutations in KRAS and EGFR are rarely found simultaneously, suggesting a similar activi-
ty in lung cancer carcinogenesis (Gazdar, Shigematsu, et al., 2004). These molecular 
targets, as well as several others, must not be overlooked and new strategies to take ad-
vantage of cellular fragilities must continue to be explored.  
 
1.4. Cancer therapeutics 
Cancer research and therapy has been approached by multifactorial targets. The aim is 
to interact with the multi-altered pathways present in cancer cells, e.g. by inducing pro-
grammed cell death, arresting cell cycle, inhibiting angiogenesis and mitigate metastatic 
behaviors with specific therapeutics. Most importantly, it is preferable that these therapeu-
tical approaches demonstrate selectivity towards cancer cells, thus sparing normal, func-
tional cells (Luo, Solimini, et al., 2009). 
The use of cancer therapeutics is a matter that must be planned with the most accurate 
and detailed diagnosis. Factors such as cancer histology, tumor phase stage and patient 
age must be considered when choosing the ideal treatment either through chemotherapy, 
radiotherapy, surgery intervention or a combination of these (Ramalingam, Owonikoko, et 
al., 2011). 
 
1.4.1.  Lung cancer treatment 
Lung cancer demonstrates the highest rate of mortality and incidence in comparison 
with other cancers. Any decrease in these rates is mostly attributed to smoking cessation 
programs rather than currently used chemo or radiotherapeutic programs. Lung cancer 
carriers, namely presenting non-small cell lung cancer (NSCLC), have an average 
lifespan of 12 months from the initial diagnosis and a 5-year survival rate of 5-10% with 
	   	   CHAPTER 1 
 
 9 
the available therapy offering no more than palliative care (Cortes-Funes, 2002; Spiro and 
Porter, 2002). Poorly implemented screening methods (mainly by a chest X-ray) are not 
sufficient to detect early pre-symptomatic stages of the disease, thus reducing the cases 
where patients are allowed to receive a treatment at an early stage where the disease 
does not yet represent a total life threat (Ramalingam, Owonikoko, et al., 2011). Chemo-
therapeutic agents are costly and the toxicity to the patient’s organism implicates a severe 
decrease in quality of life (Ramalingam, Owonikoko, et al., 2011). These factors require 
mitigation of some kind. Finding new drugs and implementing drug combinations can sig-
nificantly lower the required drug dosage, decrease side effects and ultimately improve 
the patient’s life quality.  
There are four stages of lung cancer, some of these stages are subdivided according 
to the extent of the lesions (Table 1). Early stages of NSCLC are considered to be stage I, 
stage II and certain cases of the subtype IIIA. These early stages of the disease account 
for approximately 30% of NSCLC carriers and surgical resection of all or part of the lung 
remains as the most common intervention. When a locally advanced NSCLC considered 
as surgical unresectable, medical treatment relies solely on chemotherapy or/and radio-
therapy. When applying a combination of these treatments, with changes in dose, time 
exposure, and the used chemicals, survival rates seem to improve significantly in spite of 
the high toxic intake (Ramalingam, Owonikoko, et al., 2011). The standard procedure for 
the mentioned stage of the disease varies in two regimens of treatment. The first, consist-
ing of a full dose of cisplatin and etoposide and radiotherapy, demonstrating notable side-
effects to patients, but quite efficiently eliminates small clusters of metastization (Albain, 
2002); and the second with carboplatin and paclitaxel, in a dose capable of reducing tu-
mor resistance to radiotherapy, followed by an intense dose of the combination (car-
boplatin and paclitaxel), presenting a better physical acceptance and allowing to cope with 
higher doses of radiotherapy (Belani, Choy, et al., 2005). Several improvements to current 
therapy are under test phase (Vokes, Senan, et al., 2009), and the most promising results 
are expected to arise when both radiotherapy and chemotherapy fields are equally ex-
plored and developed.  
Platinum combined drugs (e.g. carboplatin and cisplatin) are mostly indicated for ad-
vanced stages of the disease (stage IV). High neurotoxicity of these type of drugs has 
held back a wider use in other stages of the disease, thus favoring the path of combina-
tion with platinum-free drugs (Manegold, 2001). The future of NSCLC therapeutics re-
quires tumor screening in terms of genetic characteristics and development of a more 
personalized treatment (Ramalingam, Owonikoko, et al., 2011). A deeper analysis of the 
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individual’s clinical and molecular status seems suitable to a more focused and resolute 
fight against this illness.  
Doxorubicin is an anthracycline antibiotic derived from the actinobacterium Streptomy-
ces peucetius. It was discovered in the seventies and is a hydroxylated form of dauno-
rubicin. Doxorubicin is used in the treatment of a number of cancers, including lung can-
cer, and acts by interacting with the enzyme topoisomerase IIα, which leads to the accu-
mulation of DNA breaks and ultimately to cell death (Cortes-Funes and Coronado, 2007; 
Zunino and Capranico, 1990). Myelosuppression and cardiomyopathy the most common 
side effects of the use of doxorubicin and others anthracyclines (Cortes-Funes and 
Coronado, 2007). Their use in combination with other drugs is frequent practice to mini-
mize side effects, doxorubicin is extensively used in combination with etoposide and cy-
clophosphamide in the treatment of small-cell lung cancer (Cortes-Funes and Coronado, 
2007). 
 
Table 1 – The stages of lung cancer. Adapted from (LungCancer.org, 2014). 
Cancer stage Cancer sub-stage Cancer localization 
Stage I n.d Cancer exclusively located in the lungs 
Stage II 
IIA; 
Cancer in the lungs and nearby lymph nodes 
IIB 
Stage III 
IIIA; Cancer spread to lymph nodes but in the same side of his origin 
IIIB Cancer spread to lymph nodes but to a differ-ent side from its origin 
Stage IV n.d Cancer has spread to both lungs, and other organs. 
n.d – not defined 
 
1.4.2.  Drug resistance 
Drug resistance is a feature possessed by several types of cancer. Drug resistance 
represents one of the main reasons for the long-term inefficacy of chemotherapeutic 
agents. While chemotherapeutic agents may inflict a significant cytotoxicity as a treatment 
is initiated, chemo-sensitive cells in the tumor are reduced, however, chemo-resistant 
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cells are positively selected. Subsequently, chemotherapeutic agents will no longer impact 
the tumor cells to the same extent as the initial treatment (Persidis, 1999). 
Several mechanisms have been related with cancer drug resistance, for example, 
overexpression of drug transporters (e.g. P-glycoprotein, multidrug resistance protein) and 
drug-detoxifying enzymes, alterations in the membrane receptor, drug compartmentaliza-
tion, dysfunction of the apoptotic signaling pathways, increase of DNA repair ability and 
alteration of cell cycle control (Gottesman, 2002).  
The ABC transporter P-glycoprotein (P-gp) is localized in the plasma membrane of 
some cancer cells. This transporter is a target deeply implicated in the acquisition of drug 
resistance to a distinct variety of anticancer drugs (e.g. doxorubicin, etoposide, paclitaxel) 
by its ability to pump diverse drugs out of the cell. The promotor of the MDR1 gene (that 
encode for P-gp) is upregulated by diverse cellular events, such as, DNA damage; serum 
starvation, amongst others. Most of these events are triggered by the cancer cell’s initial 
response to anticancer drug toxicity (Tsuruo, Naito, et al., 2003). The link between drug 
cytotoxicity and P-gp activity validate this path as a key component for therapy targeting, 
nonetheless, it must be considered that this protein is also found in normal cells, as it is 
essential in the maintenance of homeostasis (Cordon-Cardo, O'Brien et al., 1990). Drug 
combination that allows interaction with multiple mechanisms can mitigate the deleterious 
effects of drug resistance. 
 
1.5  Drug screening 
Several approaches are employed in the search of new products with anticancer effect. 
Conventional screening includes bioactivity-guided screening and gene-guided screening. 
The National Cancer Institute (NCI) implemented a panel of sixty cancer cell lines with the 
aim to test compounds and select for further studying those that demonstrated promising 
bioactivity (Shoemaker, Scudiero et al., 2002). This method is a validation of a world ref-
erence use of bioactivity-guided screening (Covell, Huang, et al., 2007). Gene-guided 
screening where new genes responsible for the production of metabolites are searched 
based on their similarity with genes known to produce bioactive. This late methodology 
allows the identification of certain metabolites of interest from a vast number of organisms. 
Khan et al., (2010) from an initial number of 523 strains of marine bacteria was proceeded 
an analysis to evaluate the presence of 3-hydroxyl-3-methylglutaryl coenzyme A reduc-
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tase (hmgr) gene, culminating in the isolation of two compound from two strain which 
demonstrated a cytotxic effect against HL-60 cell line (Khan, Izumikawa et al., 2010).  
Once the large majority of known microorganisms are uncultured, resourcing to meta-
genomics seems a feasible method for a culture independent screening. By extracting the 
total DNA from an environment and introducing a gene in to a culturable host it is possible 
to access metabolites from organism not to be grown in vitro, and thus greatly increasing 
the ability to explore nature’s capable portfolio in its wholeness. Terragine and acyltyro-
sines, a Mycobacterium-inhibiting antibiotic are such cases of the use of metagenomics in 
the discovery of new compounds (Brady, Chao, et al., 2002; Wang, Graziani, et al., 2000). 
The uncertainty regarding the correct expression of a gene cluster in the host is one of the 
difficulties facing the use of metagenomics for the screening of natural products (Xiong, 
Wang, et al., 2013). 
Genomic strategies (Udwary, Zeigler, et al., 2007), combinatorial biology (McGlinchey, 
Nett, et al., 2008) and synthetic biology (Donia, Hathaway, et al., 2006) are also tools 
promptly utilized in the search of natural-derived products. 
 
1.6  Emerging drugs from nature 
Some diseases are currently facing changes in terms of treatment approach. In many 
cases, standard procedures are now presenting unsatisfactory results in comparison to 
their initial performance when were first implemented (Ciardiello and Tortora, 2008; Moore 
and Chaisson, 1999). For this reason, an immediate demand is rising for the search of 
new bioactive compounds and extracts. These novel bioactive molecules could ultimately 
translate into therapeutic drugs, and filling essential needs that current therapies are 
overpassing. 
Nature has always been a source of novel and potent bioactive products with therapeu-
tic applications. From 2001 to 2005, 23 nature-derived drugs reached the pharmaceutical 
market. The pharmaceutical industry has strongly invested in the bio-prospection within 
organisms, with an outcome of more than 60% of the approved drugs for cancer treatment 
from 1982 to 2002 being nature-derived (Newman, Cragg, et al., 2003). In 2007, 30 anti-
cancer microorganism-derived drugs were at some stage of clinical trials. Such examples 
of nature’s contribution are doxorubicin, daunomicin, bleomycin, mytomicin C, vincristine 
	   	   CHAPTER 1 
 
 13 
and vinblastine which all prevail in the current available treatments for cancer (Jimeno, 
Faircloth, et al., 2004). 
Notwithstanding, in the 1990s several limitations of natural products led to a disinvest-
ment of the industry, which established as a priority the use of synthetic products. 
Amongst the negative aspects of natural product bio-prospection was its incompatibility 
with high throughput screening, which aimed to potentiate the bioactivity outcome in short 
periods of time, a situation not faced with synthetic products. Labor effort to obtain quality 
and uniform batches, quantitative scarcity for drug screening and preclinical tests, mimick-
ing environmental conditions in order to stimulate the production of secondary metabolites 
in vitro similar to those in the wild and difficulty to manipulate large sized and complex 
chemical structure are some of the limitations faced (Glaser and Mayer, 2009).  The stat-
ed reasons were concomitant with the decreased interest in exploring natural products for 
pharmaceutical purpose.  
Moreover, secondary metabolites are as if inherently bioactive, as they have roles on 
defense over predation, as competitive advantage over other organisms or to communi-
cate among a population. It is certain that a basic premise for these products is the ability 
to reach at a cellular level, much like drugs must do (Beutler, 2001). Nowadays with the 
technological impulse the search in nature for bioactive compounds is thriving and in ex-
pansion (Lam, 2007).  
 
1.6.1.  Marine sourced products 
The marine environment occupies about 70% of the earth’s surface and harvests an 
estimation of 95% of the world biodiversity (Ellis, 2001). Marine species have been evolv-
ing for about 3.5 million years alongside their chemical constituents that have provided 
these organisms the ability to surpass changes in salinity and pressure, temperature ex-
tremes, predation defenses and competition for space. It is possible to find even in the 
“simplest life forms” of the ocean the precursors of some of the immune components pre-
sent in mammals (Prendergast, Lutty, et al., 1983; Scofield, Schlumpberger, et al., 1982). 
Marine-derived products are also a part of folk medicine in different cultures, as for exam-
ple, the use of seaweed-based remedies for the treatment of pain, cancer and other ill-
nesses (Ruggieri, 1976). In the last decades the interest and the accessibility towards 
marine products has greatly increased partially due to the dramatic improvement of diving 
techniques. Since then, a myriad of marine natural products with advantages and novel 
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mechanisms of action regarding currently used products have been discovered (Mayer 
and Gustafson, 2003) (Table 2). Manoalide, an unusual nonsteroidal sesterterpenoid, 
demonstrated to be first inhibitor of phospholipase A with potent analgesic and anti-
inflammatory effect, aspiring to be used in multiple disorders (Soriente, Rosa, et al., 
1999). Ecteinascidin-743, or trabectedin (ET-743, trademark Yondelis®) is a tetrahydroi-
soquinoline alkaloid and represents a successful symbol of a marine-derived drug. Re-
search, development and marketing were responsibility of the pharmaceutical company 
PharmaMar Inc. (Madrid, Spain). ET-743 is derived from a tunicate, Ecteinascidia turbi-
nate, present in the Caribbean and Mediterranean Sea (Rinehart, Holt, et al., 1990). Its 
mechanism of action, although not fully decoded, it is known to interact with the DNA, in-
hibiting transcription, and also inactivating drug resistance mechanisms (Kanzaki, Take-
bayashi, et al., 2002; Minuzzo, Mantovani, et al., 1999). ET-743 is approved in Europe for 
the treatment of soft tissue sarcoma and ovarian cancer and is undergoing different phas-
es of clinical trials for breast, lung, prostate and pediatric cancer (Verweij, 2009; Yap, 
Carden, et al., 2009). Some of the biosafety advantages for patients are the absence of 
mucositis, alopecia, neurotoxicity, cardiotoxicity or cumulative toxicities; these represent 
some of the most common side effects of current chemotherapeutic agents (Mayer, Gla-
ser, et al., 2010). 
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Table 2 – Marine derived anti-cancer drugs in the year of 2010. Adapted from (Mayer, Glaser, et 
al., 2010). 
Clinical 
status 
Compound Trademark Origin organism Chemical family 
Marketed Cytarabine, Ara-C 
Trabectedin (ET-743) 
Cytosar-U® 
Yondelis® 
Sponge 
Tunicate 
Nucleoside 
Alkaloid 
Phase III Eribulin Mesylate (E7389) 
Soblidotin(TZT 1027) 
n.d 
n.d 
Sponge 
Bacterium 
Macrolide 
Peptide 
Phase II PM1004 n.d Bacterium Peptide 
Plitidepsin Aplidin® Tunicate Depsipeptide 
Plinabulin(NPI-2358) n.d Fungus Diketopiperazine 
DMXBA (GTS-21) n.d Worm Alkaloid 
Tasidotin,Synthadotin (ILX-651) n.d Bacterium Peptide 
Elisidepsin Irvalec® Mollusc Depsipeptide 
Phase I Bryostatin 1 
Hemiasterlin 
n.d 
n.d 
Bryozoa 
Sponge 
Polyketide 
Tripeptide 
Marizomib (Salinosporamide A; 
NPI-0052) 
n.d Bacterium Beta-lactone-gama 
lactam 
n.d – not defined 
 
1.6.2.  Marine invertebrates as sources of bioactive compounds 
Sponges (Phylum Porifera) are marine invertebrates that are widely distributed world-
wide. They inhabit from the intertidal zone to deeper regions and are present not only in 
tropical waters, but also in temperate and freshwaters (Bergquist, 2001). Sponges are 
divided into 3 classes (Calcarea, Demospongiae and Hexactinellida), being the 
Demospongiae the most representative class. Regarding the simple anatomical structure 
of this sessile organism, an array of metabolites is employed by sponges to proclaim their 
space when competing with other organisms willing to occupy their surroundings (Cheng, 
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Rifkin, et al., 1968). In spite of sponges possessing specialized structures that interplay a 
role in their self-defense, chemical intervenients named secondary metabolites are a 
complementary system of major importance for the competitive oceanic ground battle 
(Wang, 2006). The pioneering studies regarding sponge secondary metabolites were un-
dertaken by Bergmann and Feeney in 1951, and lead to the isolation of nucleosides from 
Tectitethya crypta (once Cryptotethya crypta), which were later confirmed to possess anti-
viral properties (Bergmann and Feeney, 1951). Purification of sponge secondary metabo-
lites allowed the identification of macrolides, porphyrins, terpenoides, aliphatic cyclic per-
oxides, sterols, and amino acids. Arabinosyl cytosine (Ara-C), a current anticancer drug, 
Manolide (from Luffariella variabilis) an anti-inflammatory and 9-β-D-arabinofuranosyladenine 
(Ara-A) an anti-viral, are brief examples of drugs already available in the market (Thakur 
and Muller, 2004).  
 
Marine invertebrates, such as sponges, live in close relation with a microbiota commu-
nity. This symbiosis occurs with bacteria, fungi, microalgae, archae and virus and the 
symbiont can occupy up to 40% of the total sponge volume (Wilkinson, 1978). The symbi-
ont can furnish the host with some required nutrients (e.g. carbon fixation by cyanobacte-
ria). Additionally, the symbiont may also contribute to the increase of the host’s defense 
mechanisms through the production of secondary metabolites (Webster and Taylor, 
2012). 
 
1.6.3.  Marine fungi 
Marine microorganisms represent about 90% of the ocean’s biomass (Boopathy, 
Kathiresan, et al., 2010). Terrestrial fungi have been intensively explored and have pre-
sented true proof in terms of biotechnological applicability. However, marine fungi have 
gained notoriety and are also beginning to be more thoroughly explored, consequently, 
promising results are starting to appear. Some of the secondary metabolites extracted 
from marine fungi have been shown to possess anti-oxidant, anti-proliferative, anti-
inflammatory, anti-metastasis and pro-apoptotic activity (Kim and Dewapriya, 2013).  
From the halotolerant marine fungus strain Aspergillus variecolor B-17 two new qui-
none compounds were isolated, variecolorquinones A and B, presenting selective cytotox-
icity against a series of cancer cell lines. Variecolorquinone A inhibits the proliferation of 
A549 cells (IC50 of 3.0 µM), and variecolorquinone B inhibits the proliferation of HL-60 and 
P388 cells (IC50 of 1.3 µM and 3.7 µM, respectively) (Wang, Zhu, et al., 2007). 
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Dicitrinone B was first isolated from the marine-derived fungi Penicillium citrinum by Du 
et al., 2010, demonstrating cytotoxicity against HL-60, A549, BEL-7402 and MOLT-4 cells 
with IC50 values of 6.5 µM, 53.9 µM, 39.8 µM and 6.0 µM, respectively. This compound 
inhibits the proliferation of HL-60 cells by arresting cell cycle at the G2/M phase (Du, 
Zhang et al., 2010).  Recently, this compound was tested in A375 and was demonstrated 
to induce apoptotic pathways by activation of caspase 3, 8 and 9 (Chen, Gong et al., 
2014). 
The secondary metabolite (−)-phenylahistin isolated from the marine and terrestrial 
fungus Aspergillus ustus showed anti-proliferative effects by Kanoh et al. in 1997 acting 
by inhibition of tubulin polymerization inhibiting cell cycle in G2/M phase. After a series of 
chemical modifications by Yoshio et al., in 2013 in order to achieve a water-soluble pro-
drug, this compound was tested in a phase II clinical trial by Nereus Pharmaceutical (San 
Diego, CA, USA) (Hayashi, Yamazaki-Nakamura, et al., 2013; Kanoh, Kohno, et al., 1997; 
Newman and Cragg, 2014). 
 
1.6.3.1.  Neosartorya genus 
Neosartorya species are closely related with the Aspergillus genus (Rydholm, Szakacs, 
et al., 2006). Compounds isolated from the Aspergillus genus have demonstrated anti-
cancer activity both in vitro and in vivo, as evaluated by Bladt	  et al. 2013 (Bladt, Frisvad, 
et al., 2013). While the bioactivity of the secondary metabolites produced by Neosartorya 
species remains less explored, a greater potential may have been overlooked. Recently, 
several research groups have been dedicated to understanding which biotechnological 
applications can be developed from these metabolites. Present hereon are some of the 
works that demonstrated anticancer effects of secondary metabolites isolated from Ne-
osartorya species. 
Eamvijarn et al., (2013) isolated several compounds (aszonalenin, acetylaszonalenin, 
aszonapyrone B, 13-oxofumitremorgin B and aszonapyrone A) from the soil fungus Ne-
osartorya fischeri (KUFC 6344), aszonapyrone A from the diseased coral-derived fungus 
Neosartorya laciniosa (KUFC 7896) and an analogue from chevalone C from the marine 
sponge-associated fungus Neosartorya tsunodae (KUFC 9213). The cytotoxicity of the 
compounds was tested in a panel of three cancer cell lines (MCF-7, NCI-H460 and A375-
C5) with GI50 values ranging from 10.2 µM to >150 µM (Eamvijarn, Gomes, et al., 2013). 
In another study, Eamvijarn et al., 2012 isolated seven compounds (two of which reported 
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as new compounds) from the fungus Neosartorya pseudofischeri. Two of the already 
known compounds demonstrated an anti-cancer effect. One compound exhibited growth 
inhibitory activity, comparable to the effect exerted by etoposide and carboplatin in a panel 
of cancer cell lines. Another compound displayed cytostatic effect in U373 and A549 cells 
(Eamvijarn, Kijjoa, et al., 2012). 
 
Buttachon et al., 2012 isolated fourteen new compounds from the soil fungus Neosar-
torya siamensis (KUFC 6349). Eight of these compounds were evaluated in regard to 
growth inhibitory activity in U373, Hs683, A549, MCF-7 and SK-MEL-28 cancer cells, hav-
ing shown IC50 values ranging from 39 µM to >100 µM (Buttachon, Chandrapatya, et al., 
2012). 
 
Tan et al., (2011) obtained two new compounds (fischeacid and fischexanthone) and 
eight already known, from the marine-derived fungus Neosartorya fischeri strain 1008F1. 
The anti-cancer bioactivity of the compounds at a concentration of 200 µg/ml was as-
sessed in SGC-7901 and BEL-7404 cancer cell lines, showing cell proliferation inhibition 
ranging from 11.3% to 89.8%. Antiviral (tobacco mosaic virus) effect was also reported 
from some compounds found in this fungus (Tan, Ouyang, et al., 2011). 
 
Kijjoa et al. (2011) isolated 3 compounds (sartoryglabins A-C) from the fungus Neosar-
torya glabra, which demonstrated strong to moderate effect against MCF-7 cells, and 
weak or no effect against NCI-H460 and A375-C5 cells (Kijjoa, Santos, et al., 2011). 
From past to present cancer has been faced as a challenge to the scientific and medi-
cal community. Great advances have been made in the biology of cancer allowing the 
improvement of early detection of cancer and the treatments available. However the chal-
lenge remains and the multiple thematic approaches need to be further developed. Drug 
screening of new compounds derived from marine organisms could provide a significant 
improvement to current therapeutics, as demonstrated by several recent novel products. 
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2.1. Manuscript 
Abstract	  
Marine and soil fungi are promising sources for bioprospection of novel com-
pounds with applications regarding human health. This study aimed to assess 
the in vitro anticancer activities of crude ethyl acetate extracts of marine-derived 
fungi Neosartorya tsunodae KUFC 9213 (E1) and Neosartorya laciniosa KUFC 
7896 (E2) and soil fungus Neosartorya fischeri KUFC 6344 (E3), on a panel of 
seven human cancer cell lines. Initially, MTT assay was performed after 48 h 
treatments with diverse concentrations of extracts to determine the IC50 for each 
extract per cell line. Effects on DNA damage, clonogenic potential and ability to 
induce cell death were also assessed. Extract E1 did not exhibit anti-
proliferative effects. Extract E2 decreased the clonogenic potential in HCT116, 
A375, MCF7 and HT29 cells, whereas extract E3 showed such effect in 
HCT116 and MCF7 cells. Both extracts increased DNA damage in some cell 
lines. Extract E2 induced cell death in HT29, HCT116, MCF7 and A375 cells, 
while extract E3 increased death in MCF7 and HCT116 cells. Results reveal 
that extracts E2 and E3 have anticancer activities in human colon carcinoma, 
breast adenocarcinoma and melanoma cells, validating the interest for future 
identification of the compounds and molecular targets involved in the anticancer 
activity. 
 
Keywords: Marine-derived fungi; anticancer activity; anti-proliferative activity; cancer 
cell lines; cell death; Neosartorya species. 
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1. Introduction 
Cancer is one of the main causes of death in developed countries and is gaining 
lead in developing ones. Its incidence is steadily increasing in parallel with population 
growth and aging, as well as with some environmental and lifestyle factors (Jemal et 
al., 2011). The individual’s gene pool influence many be high and must be also consid-
ered (Frank et al., 2014). Since cancer has high human/social costs, all sorts of strate-
gies to prevent or treat cancer are desirable. Lifestyle changes, early detection and 
new treatments are key to prevent and reduce the cancer incidence (Jemal al., 2011). 
Considering the (i) increasing frequency of neoplastic lesions, (ii) the resistance ac-
quired to conventional common-use therapeutic drugs (Holohan et al., 2013), (iii) cross 
resistance to structurally dissimilar and unused anticancer drugs (Iseri et al., 2009), 
and (iv) undesirable side effects of current chemotherapeutic drugs, new bioactive sub-
stances are needed.   
The marine environment is a prosperous and still underexploited resource of bioac-
tivnatural compounds (Mayer et al., 2010). Bioprospection of the seas has brought to 
light numerous novel compounds that have been pinpointed as potential therapeutical 
agents, especially by demonstrating bioactive profiles with anticancer, anti-
inflammatory, anti-viral, anti-angiogenic, antioxidant and anti-adhesion activity (García 
et al., 2013; Lind et al., 2013; Mayer et al., 2013, Von and Vollmar, 2013). Trabectedin 
(Yondelis®, ET-743), is one of the few marine-derived drugs approved for clinical use 
as an anticancer medicine, more remain under clinical trial phases, as is the case of 
brentuximab vedotin (Adcetris®) and PM00104 (Zalypsis®) (Newman and Cragg, 2014) 
and of plitidepsin (Aplidin®) (Ribrag et al., 2013).  
Marine-derived fungi may be of key relevance in the quest for biopharmaceuticals 
since fungi produce metabolites with interesting bioactive activities (Greve et al., 2010). 
Moreover, marine fungi may overcome the frequent limitation of production shortfall, 
since they have the potential to be easily produced under laboratorial/industrial condi-
tions, and are therefore good candidates for compound extraction under mass-
production. Several compounds from marine fungi presented cytotoxic and cytostatic 
effects on human cancer cell lines (Pejin et al., 2013). Moreover, in extended studies 
compounds isolated from marine fungi have been found to target different pathways 
involved in proliferation and cell death mechanisms and other hallmarks of cancer. Such 
an example is cryptosphaerolide, from the marine-derived ascomycete fungal strain 
CNL-523 of the genus Cryptosphaeria sp., which induced apoptosis by the inhibition of 
Mcl-1 protein, member of the essential cell death regulatory proteins Bcl-2 family 
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(Jasperson et al., 2010). The anthraquinone SZ-685C, from Halorosellinia sp., a man-
grove endophytic fungus, had large cytotoxic effects in 6 cancer cell lines, inducing 
apoptosis by inhibition of Akt/FOXO pathway (Xie et al., 2010). Peribysin D has been 
identified as being an exceptional cell-adhesion inhibitor in HL-60 cells to HUVEC (hu-
man umbilical endothelial cell) and may be a key in preventing metastasis (Yamada et 
al., 2004).  
More recently, fungus species of the Neosartorya genus, which represent sexual 
forms of the Aspergillus species from the Fumigati section, have gained interest as 
potential sources for the isolation of potential anticancer compounds (Tan et al., 2011; 
Eamvijarn et al., 2013; Buttachon et al., 2012). With this rationale in mind, the aim of 
this study was to assess the in vitro anticancer activity of the crude extract of three fun-
gi species, marine-derived fungi Neosartorya tsunodae KUFC 9213 (E1) and Neosar-
torya laciniosa KUFC 7896 (E2) and soil fungus Neosartorya fischeri KUFC 6344 (E3) 
on a panel of seven human cancer cell lines: colon carcinoma (HT29 and HCT116), 
liver hepatocellular carcinoma (HepG2), breast adenocarcinoma (MCF7), malignant 
melanoma (A375), lung carcinoma (A549) and glioblastoma (U-251) cells.  
 
2. Material and Methods  
2.1. Reagents 
Doxorubicin (Dox), Dulbecco's Modified Eagle Medium (DMEM), Minimum Essential 
Medium Eagle medium (MEM), Roswell Park Memorial Institute medium (RPMI), 
McCoy’s 5A Modified medium, penicillin/streptomycin, trypsin solution, 4,6-diamidino-2-
phenylindole (DAPI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dimethylsulfoxide 
(DMSO) was purchased from AMRESCO LLC (Solon, SO, USA). Fetal bovine serum 
(FBS) was purchased from Biochrom KG (Berlin, Germany). All other reagents and 
chemicals used were of analytical grade. 
  
2.2. Fungal Material 
Neosartorya tsunodae (KUFC 9213) was isolated from the marine sponge Aka cor-
alliphaga, which was collected from the coral reef of the Similan islands, Phagna prov-
ince, Thailand, by scuba diving at 10 m depth, in April 2010 and the sponge was identi-
fied as described by Eamvijarn et al. (2013). The pure cultures were deposited as 
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KUFC 9213 at Kasetsart University Fungal Collection, Plant Pathology Department, 
Agriculture Faculty, Kasetsart University, Bangkok, Thailand. 
Neosartorya fischeri (KUFC 6344) was isolated from coastal forest soil at Sa-
maersarn island  Chonburi Province, Thailand, in November 2008 and identified as 
described by Eamvijarn et al. (2013). The pure cultures were deposited as KUFC 6344 
at the Mycology Laboratory, Plant Pathology Department, Agriculture Faculty, Kaset-
sart University, Bangkok, Thailand, and as IFM 59696 at the Medical Mycology Re-
search Center, Chiba University, Japan. 
Neosartorya laciniosa (KUFC 7896) was isolated from a diseased coral (ulcerative 
white spot in P. lutea) at Ao Nuan Lan island, Chonburi Province, in the Thailand Gulf, 
in May 2010 and identified as described by Eamvijarn et al. (2013). The pure cultures 
were deposited as KUFC 7896 at Kasetsart University Fungal Collection, Plant Patholo-
gy Department, Agriculture Faculty, Kasetsart University, Bangkok, Thailand, and as 
MMERU 01 at Microbes Marine Environment Research Unit, Environmental Science 
Division, Science Faculty, Ramkhamhaeng University, Bangkok, Thailand. 
 
2.3. Crude ethyl acetate extracts preparation  
Crude ethyl acetate extracts were made as described by Eamvijarn et al. (2013). 
Briefly, marine fungi were cultured in five 90 mm Petri dishes with malt extract agar 
(MEA) (for the strains KUFC 9213 and KUFC 7896) or with potato dextrose agar (for 
the strain KUFC 6344) for one week. Then Erlenmeyer flasks containing rice and water 
were autoclaved, inoculated with the respective fungus and incubated for 30 days at 
28º C. The mouldy rice was macerated in ethyl acetate, filtrated, and then the two lay-
ers were separated with a separatory funnel, and the ethyl acetate solution was con-
centrated at a reduced pressure. 
 
2.4. Cell lines 
HT29, HCT116 cells were kindly provided by Prof. Carmen Jerónimo, from CI-IPO, 
Porto. HepG2 cells were kindly provided by Prof. Rosário Martins, from ESTSP and 
CIIMAR, Porto. A375, A549, U-251 and MCF7 cell lines were obtained from European 
Collection of Cell Cultures (ECACC). Cells were maintained as monolayer cultures in 
DMEM (HT29, A375 and A549 cell lines) in MEM (HepG2, U-251 and MCF7 cell lines) 
or RPMI for HCT116 cell line. The mediums were supplemented with 10% FBS, 1% 
antibiotic solution (100 U/ml penicillin and 100 µg/ml streptomycin), 10 mM HEPES and 
0.1 mM sodium pyruvate. Cells were maintained in an incubator with a humidified at-
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mosphere of 5% CO2 at 37º C. Cells were trypsinised when approaching confluence 
and medium was changed every two days. For experiments, the test extracts and Dox 
were dissolved in DMSO (final concentration < 0.5%) and controls received DMSO 
only. 
 
2.5. Evaluation of cell viability/proliferation by MTT Assay 
Effects in cell viability/proliferation were evaluated by the MTT reduction assay 
(Ramos et al., 2008). Briefly, cells were seeded at a density of 0.8x104 to 1x104 
cell/well in 96-well plates and incubated for 24 h in 5% CO2 at 37º C. After adhesion, 
cells were exposed to fresh medium containing varying concentrations of fungi extracts 
(0.1, 1, 10, 100 and 200 µg/ml) or Dox (0.001, 0.01, 0.1, 1 and 10 µM) that was used 
as positive control. After 48 h of treatment, MTT solution at final concentration of 0.5 
mg/ml was added and incubated for 2 h at 37º C.  Ethanol-DMSO (1:1) (v/v) solution 
was used to dissolve the formazan crystals and absorbance (A) was measured at 570 
nm in a microplate reader (Multiskan EX, Labsystems, USA). The number of viable 
cells in each well was estimated by the cell’s capacity to reduce MTT and produce 
formazan crystals (Ramos et al., 2008). The concentration of extract or Dox that inhib-
its cell viability by 50% (IC50) was calculated by analysing dose-response data with 
GraphPad Prism v5.0 software (GraphPad Software, La Jolla, CA, USA). 
To evaluate effects on cell proliferation, absorbance at the beginning of incubation (t 
= 0 h) was subtracted from all the experimental conditions, including the negative con-
trol (cells without any test extract) at the end of treatment (t = 48 h). Cell proliferation 
and cell inhibition percentages were calculated according to the following equations, 
where A is absorvance; iC is initial control and fC is final control.: 
Cell proliferation (%) = [(Asample – AiC)/(AfC – AiC)] X 100 
 
Cell inhibition (%) = 100 – Cell proliferation 
 
  In this way, whereas negative values for cell proliferation imply direct cytotoxic ef-
fects of extracts, positive values (between 0 and 100%) imply inhibition of cell prolifera-
tion. The results correspond to the mean of at least six independent experiments; each 
carried out in duplicate. For the following assays, only fungi extracts inducing an IC50 
inferior to 200 µg/ml and without cytotoxic effects were used. 
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2.6. Evaluation of cytostatic effect by clonogenic cell survival assay 
Long-term cytostatic effect was evaluated by the clonogenic cell survival assay. 
Cells were seeded in 24-well plates with a density of 1 x 106 cells/ml and after adhesion 
cells were incubated with extracts and Dox at IC50 concentrations (determined above). 
After 48 h of treatment cells were harvested by trypsinization and then the survival cells 
seeded in 12-well plates at a density of 200 cells per well. Cells were incubated with 
drug-free medium for 10 days under normal culture conditions. After the incubation 
period, cells were washed with PBS and fixed in situ with 4% paraformaldehyde (in 
PBS) for 15 min at room temperature. Then, cells were stained with 0.05% crystal vio-
let for 30 min at room temperature washed with distilled water and the plates were left 
to dry. In each treatment condition, colonies made of more than ~ 50 cells were quanti-
fied by a stereomicroscope (Leica, ZOOM 2000) and the plating efficiency (PE) and 
surviving fraction (SF) were calculated according to the following equations (Franken et 
al., 2006; Munshi et al., 2005): PE = number of colonies counted/number of seeded 
cells and SF = (PE of treated cells/PE of control) x 100. 
 
2.7. Evaluation of genotoxic effect by single cell electrophoresis assay (Comet Assay) 
Effects on DNA damage were evaluated by the single cell electrophoresis assay or 
comet assay (Collins et al., 2008; Ramos et al., 2010). Briefly, cells were seeded at a 
density of 0.1 x 106 cells/ml in 24-well plates. After adhesion, cells were treated with the 
respective IC50 concentrations of fungal extracts and Dox for 4, 24 and 48 h at 37º C. 
By the end of each treatment, 2 x 104 cells were collected per sample, mixed with a 
0.5% (w/v) low melting agarose and mounted on slides previously coated with a 1% 
(w/v) normal melting agarose. Up to this point, all samples were maintained at 4ºC to 
minimize further DNA repair. Slides were placed in lysis solution (2.5 M NaCl, 100 mM 
Na2EDTA, 10 mM Tris, pH 10) plus 1% (v/v) Triton X-100 for 1h at 4º C and then incu-
bated in an alkaline electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13) for 
40 min at 4ºC to allow the DNA to unwind. After a 20 min electrophoresis at 21 V, 
slides were washed, fixed with 100% ethanol, and dried at room temperature. After-
wards slides were stained with DAPI solution at 1µg/ml, observed under a fluorescence 
microscope (Olympus IX71) and the CometScore® software (CometScore, TriTek 
Corp.) was used to calculate the parameter of percentage of tail intensity. 
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2.8. Evaluation of cell death induction by nuclear condensation assay 
Effects of test extracts on the induction of cell death were evaluated by the nuclear 
condensation assay. Cells were seeded at a density of 1 x 106 cells/ml on 24-well 
plates and incubated for 24 h at 37ºC. After adhesion, cells were treated with the re-
spective IC50 concentrations of fungi extracts and Dox and left to incubate for 48 h. In 
each well, adherent and detached cells were collected, washed, centrifuged and fixed 
with 4% (w/v) paraformaldehyde in PBS for 15 min at 37ºC. Samples were stored at 
4ºC until further use. On the day of experiment, cells were mounted on polylysine-
treated slides using a Cell Spin Cytospin centrifuge and left to air dry. Ensuing, the 
slides were thrice-washed with PBS for 5 min each and incubated for 10 min in the 
dark with DAPI (1µg/ml) for nuclei staining. The cells with condensed nuclei were ob-
served using a fluorescence microscope (Olympus IX71) and at least 300 cells were 
scored per sample. The percentage of cells with condensed nuclei was determined 
according to the following equation: % of cells with condensed nuclei = (Number of 
cells with nuclear condensation/Total number of cells) x 100. 
 
2.9. Statistical analysis 
Results are expressed as mean ± SD from at least 3 independent experiments. Sta-
tistical tests were performed by one-way ANOVA, followed by the post-hoc Newman-
Keuls multiple comparison test or Dunnett’s test or by the Student’s t-test, using the 
software GraphPad Prism v5.0 (GraphPad Software, La Jolla, CA, USA). P values ≤ 
0.05 were considered statistically significant. 
 
3. Results and Discussion 
As a first step to ground further research, the extracts were screened for anti-
proliferative activity against HepG2, HT29, HCT116, A375, A549, MCF7and U251 can-
cer cell lines. After 48 h of cell exposure to a range of concentrations of the extracts of 
marine fungi and Dox (positive control), effects on cell viability/proliferation were meas-
ured by MTT reduction assay. Impacts of extract and Dox on cell viability were summa-
rized in Table 1, by IC50 values that correspond to the concentration that was able to 
cause a 50% inhibition of viability. At the tested concentrations, the Neosartorya tsu-
nodae extract (E1) did not decrease cell viability in any of the tested cell lines (in all 
cases the IC50 was higher than 200 µg/ml). Despite, Eamvijarn et al. (2013), which in a 
recent work demonstrated that sartorypyrone B, isolated from the ethyl acetate extract 
of Neosartorya tsunodae showed an anti-proliferative effect on MCF7, A375-C5 and 
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NCI-H460 cells; however in our work crude ethyl acetate extract E1 did not demon-
strate anti-proliferative effects.  
The Neosartorya laciniosa extract (E2) was found to inhibit four of the human cancer 
cell lines tested, namely in HT29, HCT116, A375 and MCF7 cells. The IC50 value for 
that extract was 139, 141, 179 and 200 µg/ml in HCT116, A375, MCF7 and HT29, re-
spectively, showing that HCT116 and A375 cells were the most sensitive to E2.  
Neosartorya fischeri extract (E3) also presented relevant inhibitory activities (IC50 ≤ 
200 µg/ml) on HCT116 and HT29 (IC50 of 189 µg/ml and 196 µg/ml, respectively) and 
MCF7 (IC50 of 189 µg/ml), although less active than extract E2. Doxorubicin was used 
as a positive control, and was shown to decrease cell viability in all tested cell lines in a 
dose-dependent manner; the IC50 values range from 0.11 µM to 1.55 µM. The U251, 
HT29 and A549 cell lines were the most resistant ones, with an IC50 of 1.55, 0.87 and 
0.54 µM, respectively. 
 
Table 1 – IC50 values of extracts from Neosartorya tsunodae (E1), and Neosartorya laciniosa 
(E2) Neosartorya fischeri (E3) in seven cell lines determined by MTT assay.  
IC50 values are the mean at least 6 independent experiment each in duplicate. Doxorubicin was 
used as a positive control. 
 
As proposed, the effects on cell proliferation were also inferred from the MTT re-
sults. As shown in Figure 1A, extract E2 significantly inhibited cell proliferation in HT29, 
HCT116, A375 and MCF7 in a dose-dependent manner. Also extract E3 decreased cell 
 IC50 (95% confidence interval) 
Cell lines E1 (µg/ml) E2 (µg/ml) E3 (µg/ml) Doxorubicin (µM) 
HepG2 >200 >200  >200 0.11 (0.07-0.17) 
HT29 >200 200 (177-226) 196 (167-229) 0.87 (0.54-1.39) 
HCT116 >200 139 (120-164) 189 (166-214) 0.13 (0.09-019) 
U251 >200 >200 >200 1.55 (0.70-2.50) 
A549 >200 >200 >200 0.54 (0.30-0.94) 
A375 >200 141 (120-166) >200 0.12 (0.09-0.16) 
MCF7 >200   179 (154-205) 189 (156-225) 0.37 (0.27-0.50) 
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proliferation in a dose-dependent manner in HT29, HCT116 and MCF7 cells (Figure 
1B). For concentrations higher than 200 µg/ml, both extracts induced a cytotoxic effect 
(Figure 1). The percentage of inhibition of cell proliferation of extracts E2 and E3 at the 
same concentration (e.g., 100 µg/ml) are summarized in Table 2. In HCT116 and 
MCF7 cells, extract E2 inhibited cell proliferation by 45% and 69%, while extract E3 
inhibited proliferation by 26% and 39%, respectively. Contrarily, HT29 cells showed the 
lowest rates of inhibition of cell proliferation for both extracts (E2 - 24% and E3 - 19%).  
 
 
Figure 1. Dose-response effects of extracts E2 (A), E3 (B) on cell proliferation in HT29, 
HCT116, MCF7 and A375 cells after 48 h, evaluated by MTT assay. Results are expressed as 
mean + SD of at least six independent experiments, in duplicate. Significant differences (* P ≤ 
0.05; ** P ≤ 0.01 and *** P ≤ 0.001), were determined by the post-hoc Newman-Keuls multiple 
comparison test. 
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Table 2 – Effect of 100 µg/ml E2 and E3 extracts on cell proliferation (percentage of cell inhibi-
tion) after 48h of incubation.  
 
Cancer cell lines 
Percentage of cell inhibition 
(CI) 
E2 extract E3 extract 
HT29 24 19 
HCT116 45 26 
MCF7 69 39 
A375 64 n.d 
n.d – not determined 
 
Attending to changes in IC50 values and in percentages of cell inhibition between cell 
lines, it seems that the extracts may act by different pathways, depending of the genet-
ic characteristics of each cell line. Particularly, this can be suggested based on the fact 
that the drug resistance demonstrated by several types of cancers, namely colorectal 
cancer, is often related with p53 mutations (Ravizza et al., 2004). In our work, both 
extracts (E2 and E3) were more bioactive (showed lower IC50 values) in cell lines with 
wild-type p53, however, they also showed an anti-proliferative effect in the HT29 cell 
line (p53 mutant), which may indicate that the extracts may act by p53-dependent and 
independent mechanisms.   
In the cell lines most sensitive to the effect of the extracts (HCT116, A375 and MCF7), 
extract E2 was more bioactive than extract E3, which may reflect differences in the 
extracts’ chemical composition. Recently, Eamvijarn et al. (2013) isolated compounds 
from the ethyl acetate extract of the fungi N. fischeri and N. laciniosa and demonstrated 
the anti-proliferative effect of 13-oxofumitremorgin B (2) and sartorypyrone A (3) isolat-
ed from N. fischeri, aszonapyrone A (4b) isolated from N. fischeri and N. laciniosa in 
MCF7, NCI-H460 and A375-C5 cancer cell lines. GI50 values ranged from 10.2 µM to 
123.3 µM. Aszonapyrone A, present in both extract E2 and E3, was considered the 
most potent compound with GI50 around 10 µM for all the cell lines tested. Tryptoqival-
ine L, that was also isolated from the fungus N. laciniosa, showed cytotoxic effects in 
MCF7 cells (Sodngam et al., 2014). According to our data, these compounds and oth-
ers may be responsible for the anti-proliferative effect of the extract E2 and E3.  
Several marine compounds have shown strong anti-proliferative effects. Asper-
giolide B, an aromatic polyketide isolated from marine-derived Aspergillus glaucus, had 
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a strong cytotoxic effect on A549 and HL60 cell lines, with respective IC50 values of 
0.24 µM and 0.51 µM (Du, Zhu et al., 2008). The cyclic pentadepsipeptide zygospo-
ramide, isolated form marine-derived Zygosporium masonii, revealed a potent cytotoxic 
effect in a panel of 60 cell lines, with a median growth inhibition (GI50) of 9.1 µM, and 
presenting a specificity to RXF 393 and SF-268 cancer cell lines, with a GI50 of 5.0 and 
6.5 nM, respectively (Oh et al., 2006).  
Our extracts revealed anti-proliferative effects throughout the tested concentrations, 
demonstrating a dose-response effect. Such consequences are in line with morpholog-
ical changes observed by phase contrast microscope after treatments either with ex-
tracts or Dox (data not shown). The main changes were decreased cell density, in-
creasing of rounded and detached cells (that may indicate cell death), and cell shrink-
age.  
Only extracts with an IC50 ≤ 200 µg/ml and that did not induce direct cytotoxic effect 
were took for further testing, namely to assess the clonogenic potential, the percentage 
of DNA damage, and the ability to induce cell death. Therefore, extracts E2 and E3 
were selected for HT29, HCT116, MCF7 and A375 (only for E2) cell lines. 
A clonogenic assay was performed in order to assess whether the fungi extracts 
possess a long-term cytostatic effect on the ability of a single cell to proliferate into a 
viable colony (Sumantran, 2011). Cells previously exposed to extracts for 48 h were 
allowed to grow in fresh medium for 10 days, dyed, and afterward all colonies formed 
by more than 50 cells were counted. As shown in Figure 2, extract E2 presented a sig-
nificant decrease of clonogenic potential by over 90% in all tested cell lines, more spe-
cifically in HT29 (94%), HCT116 (97%), A375 (99%) and MCF7 (97%) cancer cell lines, 
compared with the (DMSO) control. Extract E3 also exhibited a strong reduction of the 
proliferative ability of a single cell to form a viable colony in MCF7 (93%) and a moder-
ate inhibition in HCT116 (25%) cells. Doxorubicin showed an almost total inhibition of 
clonogenic potential in all cell lines. These results show that both extracts E2 and E3 
(except extract E3 in HT29 cells) not only affect short term cell proliferation, in line with 
the MTT reduction assay, but also impact over indefinite proliferation mechanisms. 
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Figure 2. Effect of extract E2 and E3 on the clonogenic potential of human tumour cell lines; (A) 
HT29 cell line; (B) HCT116 cell line; (C) A375 cell line and (D) MCF7 cell line. Percentages in 
brackets are shown as the increase in relation to negative control. Results are expressed as 
mean + SD of at least three independent experiments. Significant differences (* P ≤ 0.05; ** P ≤ 
0.01 and *** P ≤ 0.001) when compared with negative control were determined by one-way 
ANOVA, followed by the post-hoc Dunnett’s test. 
 
DNA damage was determined quantitatively by a single-cell electrophoresis assay 
or comet assay (Figure 3). HCT116, MCF7 and A375 cells were exposed to IC50 con-
centrations of extracts E2 and E3 (Table 1) and Dox as a positive control for 4, 24 and 
48 h prior to the comet assay. Most of the tested cancer cell lines presented a con-
sistent increase in DNA strand breaks by one or more of the extracts, with exception to 
HT29 colon cell line (data not shown); in which neither extract (E2 and E3) produced 
effect. In MCF7 cells, extracts E2 (41.62 ± 8.18%) and E3 (28.68 ± 2.18%) significantly 
induced DNA damage relative to untreated control cells (15.94 ± 3.22%). Moreover, in 
A375 cells, extract E2 (27.17 ± 7.70%) also induced significant DNA damage in relation 
to the negative control (5.25 ± 1.05%). Extract E2 induction of DNA damage was also 
clear in HCT116 cells, with a significant induction by 25.41 ± 5.40% over 14.43 ± 
7.02% of the untreated cells, while extract E3 did not exhibit a significant difference as 
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to the negative control. Drugs that are able to induce consistent DNA damage may lead 
to cell death induction if the DNA damage is not repaired and allowed to build up (Lord 
et al., 2012).  
 
 
Figure 3. Effect of extract E2 and E3 on DNA damage in (A) HCT116, (B) A375 and (C) MCF7 
cells evaluated by comet assay. Results are the mean+ SD at least three independent experi-
ments. Significant differences (* P ≤ 0.05 and ** P ≤ 0.01) when compared with negative control 
were determined by one-way ANOVA, followed by the post-hoc Dunnett’s test. Additionally, a 
Student’s t-test was selectively used to access significant differences in HCT116 (E2), A375 
(Dox) and MCF7 (Dox) in relation to the respective control. 
 
In order to discern whether the anti-proliferative effect observed through the MTT 
reduction assay was due to the induction of cell death, nuclear condensation was ana-
lyzed after cells were subjected to a 48 h exposure to the respective IC50 values of ex-
tracts E2 and E3 (Figure 4). When analyzing nuclear condensation, a significant in-
crease in the number of cell death was detected in most of the tested cell lines after 
treatment with extracts E2 and E3. Extract E3 exhibited a 19% increase cell death in 
HCT116 cells and a 10% increase in MCF7 cells in relation to the negative control. 
Extract E2 presented a broader induction of cell death, having induced a significant 
increase of cell death in all tested cell lines. In colon carcinoma cell lines, extract E2 
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lead to an increment of 12% in HT29 cells and 17% in HCT116 cells regarding the 
negative control. Moreover, extract E2 presented a 13% increase in A375 cells and 
17% in MCF7 cells, in comparison to the negative control. Interestingly, extract E2 
showed a significantly higher induction of cell death than the positive control Dox in 
HCT116 and MCF7 cell lines. As referred before, some compounds isolated from ex-
tract E2 and E3 showed anti-proliferative effects however effects on cell death still un-
known. 
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Figure 4. Effect of extract E2 and E3 on the induction of nuclear condensation in (A) HT29, (B) 
HCT116, (C) A375 and (D) MCF7 cells assessed by nuclear condensation assay. Percentages 
in brackets correspond to the increase in relation to negative control. Results are displayed as 
the mean +SD of at least three independent experiments. Significant differences (* P≤0.05; ** 
P≤0.01 and *** P≤0.001) when compared with negative control were determined by one-way 
ANOVA, followed by the post-hoc Dunnett’s test. Additionally, a Student’s t-test was selectively 
used to access significant differences in HT29 (E2) in relation to the control. 
 
	   	   CHAPTER 2 
 
 43 
In summary, extract E2 decreased cell proliferation in HT29, HCT116, A375 and 
MCF7 cells at both short and long-term, by decreasing the proliferative ability of a sin-
gle cell to form a viable colony. Besides the anti-proliferative effects, extract E2 also 
showed an induction of cell death in part due to the induction of DNA damage. Extract 
E3 demonstrated an anti-proliferative effect at both short and long-term and cell death 
induction in HCT116 and MCF7 cells. However the mechanisms involved on induction 
of cell death seems to be in part different, since in HCT116 cells extract E3 did not in-
duce DNA damage. Extract E3 also decreased proliferation in HT29 cells, however this 
decrease was only observed at short-term and without effect on cell death. These re-
sults show for the first time that Neosartorya laciniosa (KUFC 7896) and Neosartorya 
fischeri (KUFC 6344) crude ethyl extracts have anticancer activity in human colon car-
cinoma, breast adenocarcinoma and malignant melanoma cells by decreasing cell pro-
liferation and increasing cell death. The investigation of transduction pathways and 
molecular targets involved on anticancer effects of extracts should be partaken in fur-
ther studies. Also, this study supports the pertinence of further efforts for characterizing 
the exact bioactive compounds of the extracts that are involved in the effects we dis-
closed. 
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CHAPTER 3 
 
MARINE-DERIVED FUNGI EXTRACTS AND ISOLATED COMPOUNDS 
ENHANCE THE ANTICANCER ACTIVITY OF DOXORUBICIN IN  
NON-SMALL CELL LUNG CANCER CELLS  
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3.1. Manuscript 
Abstract: In view that drug resistance is a major concern in current chemo-
therapeutic approaches and that fungi (including of marine origin) are prom-
ising sources for bio-prospection of novel anticancer compounds, this study 
assessed firstly the in vitro anticancer activity of crude ethyl extracts of 
seven fungi — Neosartorya tsunodae (E1), Neosartorya laciniosa (E2), Ne-
osartorya fischeri (E3), Aspergillus similanensis (E4), Neosartorya pau-
listensis (E5), Talaromyces trachsypermus (E6) and Neosartorya siamensis 
(E7) — when combined with doxorubicin, in a panel of seven cancer cell 
lines. Thenafter, the effect on cell viability of eight compounds isolated from 
extract E7, 2,4-dihydroxy-3-methylacetophenon (C1), nortryptoquivaline 
(C2), chevalone C (C3), tryptoquivaline H (C4), fiscalin A (C5), epi-fiscalin 
C (C6), epi-neofiscalin A (C7) and epi-fiscalin A (C8) was selectively evalu-
ated in combination with doxorubicin in A549 lung cancer cells. Extracts E1, 
E7 and E2 demonstrated a significant enhancement of doxorubicin’s cyto-
toxic activity, while also increasing cell death in A549 cells. All isolated 
compounds (except C1), potentiate the cytotoxicity of doxorubicin in A549 
cells, some even more so than the originary extract. We concluded that the 
tested fungal extracts potentiate the anticancer action of doxorubicin, inhib-
iting cell proliferation and inducing cell death in A549 cells, while isolated 
compounds also enhance the activity of doxorubicin, validating the interest 
in these combinations. The data support that further studies are worth mak-
ing, to characterize drug interactions and underlying mechanisms. 
Keywords: Drug combinations; A549 cell line; in vitro anticancer activity; 
marine-derived fungi extracts; non-small cell lung carcinoma; Neosartorya 
sp.; Aspergillus sp.; Talaromyces sp. 
Abbreviations: Doxorubicin (Dox); Dimethyl sulphoxide (DMSO); Neosar-
torya tsunodae KUFC 9213 (E1); Neosartorya laciniosa KUFC 7896 (E2); 
Neosartorya fischeri KUFC 6344 (E3); Aspergillus similanensis KUFA 0013 
(E4); Neosartorya paulistensis KUFC 7894 (E5); Talaromyces trachsyper-
mus KUFC 0021 (E6) and Neosartorya siamensis KUFA 0017 (E7); 2,4-
Dihydroxy-3-methylacetophenon (C1); Nortryptoquivaline (C2); Chevalone 
C (C3); Tryptoquivaline H (C4); Fiscalin A (C5); Epi-fiscalin C (C6); Epi-
neofiscalin A (C7); Epi-fiscalin A (C8). 
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1. Introduction 
 
Lung cancer is a globally disseminated disease, having high mortality rates and 
an increment of more than a million new cases annually [1]. Non-small cell lung can-
cer (NSCLC) accounts for the great majority of lung cancer cases, yet there is still a 
lack of an efficient therapeutic protocol able to offer patients a better survivorship and 
an acceptable quality of life [2]. Also, drug resistance in lung cancer is a problem [3]. 
Indeed, this issue in lung and other cancer cells is an important concern for the med-
ical and research community, as drug resistance is too often easily acquired by those 
cells during the administration of standard chemotherapeutic treatment [4]. Several 
mechanisms has been proposed in the acquisition of resistance, such as reduction of 
drug uptake, activation of drug detoxification, increase drug efflux and DNA repair 
capacity, and deflecting apoptotic pathway [5]. P-glycoprotein (P-gp) and multi-drug 
resistance-associated proteins (MRPs) are some of the best-known parts involved in 
drug resistance, and motivate tumor insensitivity to chemotherapeutic agents, where 
drugs are actively pumped from the cell to the outer membrane [6]. In the particular 
case of lung cancer, the lung resistance-related protein (LRP) is associated with lung 
cancer cell resistance to treatment with doxorubicin (Dox), consequently having an 
active role in the chemo-resistance of NSCLC to treatment [7]. A current approach to 
overcome this problem is the exploration of multi-drug combinations in an attempt to 
implement multi-target therapy as an alternative treatment, by affecting diverse cellu-
lar mechanisms implicated in cell resistance (e.g. drug uptake, drug metabolism, 
formation of DNA damage, DNA repair) and which can result in cell death [8]. This 
strategy has been increasingly implemented in diverse types of cancer [9,10]. 
The marine environment has proven to exert a selective pressure favorable to the 
production of novel and potent bioactive secondary metabolites by marine organisms 
[11]. Bio-prospection of marine-derived products is currently one of the main interests 
of pharmaceutical research, and several bioactive attributes have been found in those 
compounds, such as antibacterial, anti-diabetic, antifungal, anti-inflammatory, anti-
protozoal, anti-tuberculosis, and antiviral activities [12]. Several products are current-
ly under clinical trials, while others are already available as therapeutic agents for 
cancer patients (e.g. Citosar-U® and Yondelis®) [13].  
Attending to the anticancer potential of marine products, we can logically reason 
that their combination with conventional anticancer drugs may constitute a strategy to 
overcome cancer drug resistance and mitigate some of the hazardous side effects 
associated to chemotherapy, possibly by decreasing the administrated dose of these 
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agents. Considering this rationale, the aim of our study was to assess whether the 
combination of the ethyl acetate extracts of six marine-derived fungi, namely Neosar-
torya tsunodae KUFC 9213 (E1), Neosartorya laciniosa KUFC 7896 (E2), Neosar-
torya fischeri KUFC 6344 (E3), Aspergillus similanensis KUFA 0013 (E4), Neosar-
torya paulistensis KUFC 7894 (E5), Talaromyces trachsypermus KUFC 0021 (E6) 
and Neosartorya siamensis KUFA 0017 (E7), enhanced the in vitro anti-cancer activi-
ty of doxorubicin on a panel of seven human cancer cell lines (HT29, HCT116, A375, 
A549, MCF7, U251 and HepG2 cells). Effects on cell viability and induction of DNA 
damage and nuclear condensation were evaluated. Furthermore, eight compounds 
isolated from Neosartorya siamensis KUFA 0017 (E7) — a) three quinazoline deriva-
tives, nortryptoquivaline (C2), tryptoquivaline H (C4) and tryptoquivaline F (C9); b) 
four pyrazinoquinazoline derivatives, fiscalin A (C5), epi-fiscalin C (C6), epi-
neofiscalin A (C7) and epi-fiscalin A (C8); c) the meroterpenoid chevalone C (C3); 
and d) 2,4-dihydroxy-3-methylacetophenon (C1) — were also evaluated for cell via-
bility effect in combination with doxorubicin, in the A549 lung cancer cell line. With 
this assays we initiate exploring the hypothesis that because of their properties and 
anticancer potential these compounds may enhance doxorubicin’s cytotoxic activity. 
 
 
2. Materials and methods 
 
2.1. Reagents  
 
Doxorubicin (Dox), Dulbecco's Modified Eagle Medium (DMEM), Minimum Essen-
tial Medium Eagle medium (MEM), Roswell Park Memorial Institute medium (RPMI), 
McCoy’s 5A Modified medium, penicillin/streptomycin solution, trypsin solution, 4,6-
diamidino-2-phenylindole (DAPI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Dimethyl sulfoxide (DMSO) was purchased from AMRESCO LLC (Solon, 
SO, USA). Fetal bovine serum (FBS) was purchased from Biochrom KG (Berlin, 
Germany). All other reagents and chemicals used were of analytical grade.  
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2.2. Fungal material 
 
This study evaluated the effect of six marine-derived fungi, namely Neosartorya 
tsunodae (KUFC 9213) isolated from the marine sponge Aka coralliphaga, Neosar-
torya siamensis (KUFA 0017) isolated from a sea-fan (Rumphella sp.), Neosartorya 
laciniosa (KUFC 7896) isolated from a diseased coral (P. lutea ulcerative white spot), 
Aspergillus similanensis (KUFA 0013) isolated from the marine sponge Rhabdermia 
sp., Neosartorya paulistensis (KUFC 7897) isolated from the marine sponge Chon-
drilla australiensis, Talaromyces trachsypermus (KUFC 0021) isolated from the ma-
rine sponge Clathria reianwardii, and a soil-derived fungus, Neosartorya fischeri 
(KUFC 6344) isolated from coastal forest soil. The species were isolated and identi-
fied as described by Eamvijarn et al., (2013) and Gomes et al., (2014) [14, 15].  
 
2.3. Crude ethyl acetate extracts preparation  
 
Crude ethyl acetate extracts were prepared as previously described by Eamvijarn 
et al., 2013 and Gomes et al., 2014 [37,36]. Briefly, marine fungi were cultured in five 
90 mm Petri dishes with malt extract agar (MEA) (for the strains KUFC 9213, KUFC 
7896, KUFA 0013, KUFC 7897 and KUFA 0021) or with potato dextrose agar (for the 
strains KUFC 6344 and KUFA 0017) for one week. Then Erlenmeyer flasks contain-
ing rice and water were autoclaved, inoculated with the respective fungus and incu-
bated for 30 days at 28º C. The mouldy rice was macerated in ethyl acetate, filtrated, 
the two layers were separated with a separatory funnel and the ethyl acetate solution 
was concentrated at a reduced pressure.  
 
2.4. Metabolite extraction 
 
The isolation of compounds from crude ethyl acetate of Neosartorya siamensis 
(KUFA 0017) was realized by Prof. Anake Kijjoa from ICBAS, as described in But-
tachon et al., 2012, with some modifications [16]. The isolated compounds were: 2,4-
dihydroxy-3-methylacetophenon (C1), nortryptoquivaline (C2), chevalone C (C3), 
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tryptoquivaline H (C4), fiscalin A (C5), epi-fiscalin C (C6), epi-neofiscalin A (C7) and 
epi-fiscalin A (C8). 
 
 
2.5. Cell culture  
 
A375 (malignant melanoma), U-251 (human glioblastoma), MCF7 (human breast 
adenocarcinoma) and A549 (non-small cell lung cancer) cell lines were purchased 
from ECACC. HepG2 cell line was generously offered by Prof. Rosário Martins from 
CIIMAR, Porto. HT29 and HCT116 (colon carcinoma) cell lines were provided by 
Prof. Carmen Jerónimo from IPO, Porto. All cell lines were maintained in a humidified 
atmosphere at 37ºC and 5% CO2 in a cell culture incubator. Cell lines were main-
tained in MEM (HepG2, U251 and MCF7), DMEM (HT29, A375 and A549) and RPMI 
(HCT116). All mediums were supplemented with 1 % antibiotic solution (100 U/ml 
penicillin and 100 µg/ml streptomycin), 10 mM HEPES, 0.1 mM sodium pyruvate and 
10% FBS. Medium was replaced every two days and tripsinization was performed 
once a week, or when cells reached a high confluence state (>80%). 
Stock solutions of extracts, compounds and doxorubicin were dissolved in DMSO 
and stored at -20ºC. When initiating an experiment, extracts, compounds and doxo-
rubicin were dissolved in fresh medium with a maximum concentration of 0.5% 
DMSO. Negative controls were prepared with fresh medium with 0.5% of DMSO. 
 
 2.6. Evaluation of the effects of fungi extracts/compounds combined with doxorubi-
cin on cell viability by MTT reduction assay 
 
To evaluate the effect of fungi extracts in combination with doxorubicin on cell via-
bility, each cell line (HT29, HCT116, A375, A549, MCF7, U251 and HepG2 cells) 
was plated in 96-multiwell culture plates at densities ranging from 0.8x104 to 1x104 
cells/ml (according to each cell line). Cells were incubated at 37ºC and 5% CO2 for 
24 h until adhered. After adhesion, the medium was removed and new medium con-
taining fungi extracts at 100 µg/ml alone or combined with Dox (IC50 of each cell line) 
was added to the cells. Cells incubated with Dox alone or with the vehicle solvent 
were used as a positive and negative control, respectively. All conditions contained 
medium with a maximum of 0.5% of DMSO.  
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To assess the effect of the compounds isolated from Neosartorya siamensis 
(KUFA 0017) on cell viability, A549 cells were plated in 96-multiwell culture plates at 
0.8x104 cells/ml. After cell adhesion, the medium was removed and cells were incu-
bated with fresh medium containing the isolated compounds, 2,4-dihydroxy-3-
methylacetophenon (C1), nortryptoquivaline (C2), chevalone C (C3), tryptoquivaline 
H (C4), fiscalin A (C5), epi-fiscalin C (C6), epi-neofiscalin A (C7), epi-fiscalin A (C8) 
at different concentrations (1, 10, 50 and 100 µM) alone or combined with Dox at 
0.54 µM (IC50). Cells were incubated for 48 h at 37ºC and 5% CO2. 
After 48 h of incubation with the extracts/compounds alone or combined with Dox, 
MTT to a final concentration of 0.5 mg/ml was added to the initial negative control (t = 
0 h), and removed after 2 h incubation at 37ºC. The plate incubated for the remaining 
46 h at 37ºC, 5% CO2. At 48 h, MTT (0.5 mg/ml) was added to the remaining treat-
ment conditions, and followed by 2 h incubation at 37ºC and 5% CO2. To dissolve the 
formazan crystals, medium was removed, and 150 µl of organic solvent ethanol-
DMSO (1:1) (v/v) was added to each well, and incubated for 10 min in a microplate 
shaker, protected from light. Optical density (O.D) was measured at a wavelength of 
570 nm in a microplate reader (Multiskan EX, Labsystems, USA).  
Cell viability (equation 1) was estimated by the cell ability to metabolize the MTT 
and was expressed as the percentage relative to negative control (cells treated with 
medium with 0.5% DMSO). The results correspond to the mean of at least three in-
dependent experiments; each one was carried out in duplicate. Cell growth during 
the experiment in the negative control were assessed by the increase of the number 
of cells in relation at t = 0 h. For the following assays, only the fungal extracts that 
decreased cells viability when in combination with Dox were used. 
(Equation 1) Cell viability (%) = A sample x 100/ A control, where A corre-
sponds to the optical density of sample at 570 nm.    
 
2.7. Evaluation of genotoxic effect of fungi extracts when combined with doxorubicin 
by comet assay  
 
A single cell alkaline electrophoresis assay (comet assay) was applied in order to 
assess whether the tested extracts/combinations caused DNA damage in the form of 
DNA single-strand breaks and alkali-labile sites. A549 cells were seeded at a density 
of 0.1 x 106 cells/ml in 24-well plates and incubated for 24 hours at 37ºC and 5% CO2 
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until adhered. After adhesion, the medium was removed and new medium containing 
fungi extracts (100 and 200 µg/ml) and Dox (0.54 and 0.10 µM), either alone or in 
combination, was added to cells. After 24 and 48 h of incubation, medium was re-
moved and cells washed with PBS and trypsinized. An amount of 5x104 cells was 
collected from each condition and mixed with 100 µl of 0.5% (w/v) low melting point 
agarose and subsequently 70 µl of cells were set in microscope slides coated with 
1% (w/v) of normal melting agarose. Slides were incubated overnight at 4ºC in a lysis 
solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris, pH 10) with the addition of 1% 
(v/v) Triton X-100. Prior to the electrophoresis, slides were incubated for 40 min at 
4ºC in an alkaline electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13) for 
40 min at 4ºC. The electrophoresis was performed in a horizontal electrophoresis 
chamber for 20 min (1V/cm). Samples were stained with DAPI (1 µg/ml) in the dark 
for 10 min before analysis by fluorescence microscopy (Olympus IX71). A minimum 
of 100 cells was scored per sample using CometScore® software (CometScore, 
TriTek Corp.) and percentage of tail intensity quantified. 
 
 
2.8. Evaluation of the effects on cell death induced by marine-derived fungi extracts 
when combined with doxorubicin through nuclear condensation assay 
 
The observation of cells presenting nuclear chromatin condensation was per-
formed in order to assess the induction of cell death. A549 cells were seeded in the 
appropriate medium at a density of 0.1 x 106 cells/ml in 24-multiwell plates and incu-
bated for 24 h at 37ºC and 5% CO2 until adhered. After adhesion, the medium was 
removed and new medium containing fungi extracts (100 and 200 µg/ml) and Dox 
(0.1 and 0.54 µM), either alone or in combination, was added to the cells. Cells were 
incubated for 48 h at 37ºC and 5% CO2. After the incubation, cells were washed, 
trypsinized and both non-adhered and adhered cells were collected. Samples were 
then centrifuged several times to isolate cells, which were then fixed with 4% para-
formaldehyde (w/v) in PBS. The samples were mounted on poly-L-Lysine coated 
microscope slides using a Cell Spin Cytospin centrifuge (Thermo Scientific, USA) 
and stained with DAPI (1 µg/ml). Quantification of cells with condensed nuclei was 
attained by fluorescence microscopy (Olympus IX71). The percentage of cells with 
condensed nuclei was calculated from the ratio between cells with nuclear condensa-
tion and total number of cells. More than 300 cells were counted per sample.  
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2.9. Statistical analysis 
 
The statistical analyses were performed with GraphPad Prism v6.0 software 
(GraphPad Software, La Jolla, CA, USA). Results were expressed as mean ± SD 
from at least 3 independent experiments. Outlier detection was performed using a 
ROUT test (Q=10%), as included in the cited software. Data were analysed for ho-
mogeneity of variances and normal distribution using the Bartlett’s test and Kolmogo-
rov-Smirnov test, respectively. A one-way ANOVA was performed to assess signifi-
cant differences (p ≤ 0.05) between treatment conditions and control, followed by 
post hoc Newman-Keuls multiple comparison test. An unpaired Student’s t-test was 
used to verify significant differences, in selected pair comparisons of special interest. 
 
3. Results 
 
3.1. Evaluation of fungi extracts effects on cell viability by the MTT colorimetric assay 
 
Alterations in cell viability of the cancer cell lines HepG2, HCT116, HT29, A549, 
A375, MCF-7 and U251 in response to a combinatory regimen of extracts (E1, E2, 
E3, E4, E5, E6 and E7) + Dox were assessed by an MTT colorimetric assay. Extracts 
were tested at the concentration of 100 µg/ml in combination with Dox at IC50 for 
each cell line, and then represented as (100/0.54) 1 in the case of A549 cells. Attend-
ing that the values of the IC50 of these extracts alone range from 124 µg/ml to > 200 
µg/ml (previous data), a lower concentration of extracts was used (100 µg/ml) in 
combination with Dox. The negative control exhibited significant cell growth over a 
period of 48 h for all cell lines demonstrating that the cells were in the exponential 
growth phase (data not shown). 
Only three extracts (E1, E2 and E7) in A549 lung cancer cell line presented statis-
tically relevant (p < 0.05) results regarding the effect on cell viability when combined 
with Dox in comparison with cells treated with Dox alone. None of the remaining fun-
gi extracts combined with Dox in A549 and other cell lines exhibited a statistically 
significant decrease in cell viability when compared with Dox alone (data not shown). 
Results from the cell viability of A549 cell line (Figure 1) are expressed as the per-
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 From this point on, the notation, e.g. E+Dox (100/0.54), refers to extract at 100 µg/ml and Dox at 0.54 
µM in A549 cells. Combinations with compounds and doxorubicin, e.g. C+Dox (100/0.54,) refer to com-
pound at concentrations in µM and Dox in concentrations in µM. 
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centage in relation to the negative control. Dox alone (0.54 µM) exhibited a marked 
effect in cell viability, representing a 40% decrease in cell viability in relation to the 
negative control. Also, extract E7 presented a significant decrease in cell viability, by 
21%, when compared with the negative control. Extracts E1 and E2 at 100 µg/ml, 
exhibited a slight decrease in cell viability although not statistically significant when 
compared to the negative control. The combinatory regimens of extract E1+Dox 
(100/0.54); extract E7+Dox (100/0.54) and extract E2+Dox (100/0.54) manifested a 
significant cell viability inhibition of 26%, 22% and 26%, respectively, when compared 
with the positive control.  
Subsequent assays were performed only with extract E1, E2 and E7 in the A549 
lung cancer cell line, as a consequence of the results obtained in the screening test 
by the MTT assay, which demonstrated that the other extracts combined with Dox 
did not increase the cytotoxic effect of Dox in any of the cell lines tested.  
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Figure 1 – Effect of extracts E1, E2, E7 at 100 µg/ml alone and in combination with Dox at 
0.54 µM on cell viability of the A549 lung cancer cell line. Percentages in brackets refer to a 
decrease in cell viability in relation to the negative control (medium with 0.5% DMSO) or posi-
tive control (Dox at 0.54 µM). Results are the mean + SD of at least four independent experi-
ments. Significant differences (** p ≤ 0.01, *** p ≤ 0.001) when compared with the negative 
control and (## p ≤ 0.001) with the positive control (Dox alone) were determined by a one-
way ANOVA followed by the post-hoc Newman-Keuls multiple comparison test.   
	  
3.2. Effects on DNA damage induction by marine fungi extracts combined with Dox 
 
The comet assay was used to evaluate if the combination of extracts and Dox has 
genotoxic activity, by inducing DNA damage (via DNA strand breaks and alkali-labile 
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sites) in the A549 lung cancer cell line after 24 h and 48 h of treatment. Results (% of 
DNA in tail) were expressed in percentage relative to the negative control, reflecting 
the increase of DNA damage in comparison to control. At 24 h, no genotoxicity was 
observed (data not shown). However, significant results were observed with a 48 h 
exposure time (Figure 2). Dox (0.10 and 0.54 µM) alone was not able to induce a 
significant increase of DNA damage assessed by comet assay. Also, none of the 
treatments in which E1 was used showed any statistically relevant increase of DNA 
damage relative to the use of Dox alone (Figure 2A). In the case of extract E7, only 
the combination of E7+Dox (200/0.54) exhibited a significant increase of 12% in DNA 
damage, in comparison to the negative control, and 10% relative to Dox at 0.54 µM 
alone (Figure 2B). None of the remaining results had statistical relevance when com-
pared with the respective control. Figure 2C shows that E2 alone, at 200 µg/ml, sig-
nificantly increases DNA damage in 9% relative to the negative control. Increase of 
DNA damage in comparison to the positive control was observed in E2+Dox. The 
combinations of E2+Dox (200/0.10) and E2+Dox (200/0.54) induced an increase of 
5% and 9% in comparison with Dox at 0.1 µM and 0.54 µM, respectively. 
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Figure 2 – Effect of extracts E1 (A), E7 (B), E2 (C) at 100 µg/ml and 200 µg/ml alone and in 
combination with Dox at 0.1 µM and 0.54 µM on the induction of DNA damage in A549 cell 
line assessed by comet assay. Percentages in brackets refer to the increase of DNA damage 
in relation to the negative control (medium with 0.5% DMSO) or positive control (Dox at 0.1 
µM or 0.54 µM). Results are the mean + SD of at least three independent experiments. Signif-
icant differences (*p ≤ 0.05) when compared with the negative control, and (## p ≤ 0.01) 
when compared with Dox at 0.54 µM, were determined by a one-way ANOVA followed by the 
post-hoc Newman-Keuls multiple comparison test. Additionally, an unpaired Student’s t-test 
was used to determine significant differences (++ p ≤ 0.01) between extract E2+Dox 
(200/0.10) at in relation to the positive control (Dox at 0.10 µM).  
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3.3. Assessment of cell death induced by marine fungi extracts in combination with 
doxorubicin by a nuclear condensation assay 
 
Nuclear chromatin condensation was assessed in the A549 cell line after 48 h ex-
posure to the different combination regimens, as described in material and methods 
section. As shown in Figure 3, the positive controls for this experiment, Dox at 0.10 
µM and 0.54 µM induced a significant increase in the percentage of cells with nuclear 
condensation by 6% and 8%, respectively, when compared with the negative control 
(cells incubated with medium and 0.5% DMSO). Regarding the combinations with 
extract E1, both the E1+Dox (100/0.54) and E1+Dox (200/0.54) exhibited a statisti-
cally significant increase of 19% and 22%, respectively, when comparing with Dox 
0.54 µM alone (Figure 3a). Combinations with extract E7, namely E7+Dox (100/0.54) 
and E7+Dox (200/0.54) were also able to induce a significant increase in cells pre-
senting nuclear condensation, by exhibiting a 8% and 23% increase, respectively, in 
comparison with Dox 0.54 µM (Figure 3B). The combination of Dox with extract E2 
allowed the observation of a greater induction of cells with nuclear condensation 
when compared to the other extracts (E1 and E7) in combination with Dox. The com-
bination of E2+Dox (200/0.54) caused an increase of 28% in relation to Dox 0.54 µM 
alone. The combination of E2+Dox (100/0.54) exhibited an increase of 10% in com-
parison with Dox 0.54 µM alone (Figure 3C). None of the results regarding extracts 
E1, E7 or E2 at 100 µg/ml or 200 µg/ml combined with Dox at 0.10 µM were able to 
induce a significant increase in the number of cells with nuclear condensation when 
compared with Dox 0.10 µM alone.  
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Figure 3 – Effect of extracts E1 (A), E7 (B), E2 (C) at 100 µg/ml and 200 µg/ml alone and in 
combination with Dox at 0.1 µM and 0.54 µM on the induction of nuclear condensation in 
A549 cell line. Percentages in brackets refer to the increase in cells with condensed nuclei in 
relation to the negative control (medium with 0.5% DMSO) or positive control (Dox at 0.1 µM 
or 0.54 µM), respectively. Results are the mean + SD of at least three independent experi-
ments. Significant differences (# p ≤ 0.05) when compared with the negative control and (*p ≤ 
0.05; ** p ≤ 0.01 and *** p ≤ 0.001) when compared with the respective positive control, were 
determined by a one-way ANOVA followed by the post-hoc Newman-Keuls multiple compari-
son test. Additionally, an Student’s t-test was used to determine significant differences (+ p ≤ 
0.05) between Dox at 0.10 µM in relation to the negative control.  
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3.4. Evaluation of the effect of eight compounds isolated from Neosartorya siamensis 
in combination with doxorubicin on A549 cell viability by an MTT reduction assay 
 
The A549 cells were exposed to the isolated compounds (1, 10, 50 and 100 µM) 
alone or with Dox 0.54 µM (IC50) for 48 h. An MTT assay was made to assess the 
effect on cell viability of these compounds alone and in combination with Dox; only 
significant (p < 0.05) decreases in cell viability in relation to Dox will be presented.  
As shown in Figure 4, Dox at 0.54 µM significantly decreased cell viability by 45 % 
in relation to the negative control. The cytotoxic effect of Dox increased when com-
bined with compounds, except in the case of 2,4-dihydroxy-3-methylacetophenone 
(C1) that did not demonstrate a significant decrease in cell viability when compared 
with Dox 0.54 µM alone. However, compound C1, when used alone at 1 µM, demon-
strated to decrease cell viability by 32% in comparison with the negative control (Fig-
ure 4A). Nortryptoquivaline (C2) combined with Dox 0.54 µM enhanced the cytotoxic 
effect by 32% (C2+Dox (50/0.54)) and 42% (C2+Dox (100/0.54)) in comparison to 
Dox 0.54 µM alone. Nortryptoquivaline (C2), when used alone at 1, 10, 50 and 100 
µM, demonstrated to decrease cell viability by 22%, 14%, 22% and 43%, respective-
ly, in comparison with the negative control (Figure 4B). Chevalone C (C3) combined 
with Dox 0.54 µM increased the effect by 14% (C3+Dox (50/0.54)) and 24% (C3+Dox 
(100/0.54)) in comparison to Dox 0.54 µM alone; none of the remaining combinations 
of C3 and Dox expressed a significant decrease in cell viability. Chevalone C (C3), 
when used alone at 50 µM, and 100 µM demonstrated to decrease cell viability in 
25%, 44%, respectively, in comparison with the negative control (Figure 4C). Tryp-
toquivaline H (C4), combined with Dox 0.54 µM significantly increased the effect of 
Dox 0.54 µM by 22% in (C4+Dox (50/0.54)) and 30% in (C4+Dox (100/0.54)); none 
of the remaining combinations of C4 and Dox expressed a significant decrease in cell 
viability. Compound C4, when used alone at 50 µM and 100 µM, demonstrated ability 
to decrease cell viability by 29% and 30%, respectively, in comparison with the nega-
tive control (Figure 4D). Fiscalin A (C5) combined with Dox 0.54 µM enhanced the 
effect by 20% (C5+Dox (50/0.54)) and 31% (C5+Dox (100/0.54)) in comparison to 
Dox 0.54 µM alone. The remaining combinations of C5 and Dox did not express a 
significant decrease in cell viability. A549 cells treated alone with compound C5 at 
100 µM demonstrated a decrease on cell viability of 38%, in comparison with the 
negative control (Figure 4E). Epi-fiscalin C (C6) combined with Dox 0.54 µM en-
hanced the effect of Dox by 20% (C6+Dox (50/0.54)) and 31% (C6+Dox (100/0.54)). 
None of the remaining combinations of compound C6 and Dox expressed a signifi-
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cant decrease in cell viability. Epi-fiscalin C (C6), when used alone at 50 µM and 100 
µM, decreased cell viability by 34% and 41% respectively, in comparison with the 
negative control (Figure 4F). Epi-neofiscalin A (C7) combined with Dox 0.54 µM sig-
nificantly enhanced the cytotoxic effect by 24% (C7+Dox (50/0.54)), and 34% 
(C7+Dox (100/0.54)) in comparison to Dox 0.54 µM alone. When used alone, com-
pound C7 was unable to induce a significantly decrease in cell viability in comparison 
with the negative control in any of the tested concentrations (Figure 4G). Epi-fiscalin 
A (C8) combined with Dox 0.54 µM significantly increased the effect of Dox by 20% 
(C8+Dox (50/0.54) and 23% (C8+Dox (100/0.54)). None of the remaining combina-
tions and C8 alone exhibited a significant decrease of cell viability when compared 
with the respective controls (Figure 4H). 
 
Table 1 – Half maximal inhibitory concentrations (IC50) and respective 95% confidence inter-
vals of compounds C1 to C8 regarding the A549 lung cancer cell line. 
 
N.D – not determined 
 
Table 1 demonstrates the half maximal inhibitory concentrations (IC50) of the 
compounds C1 to C8. Chevalone C (C3) exhibited the lowest IC50 value (118.9 µM) 
of all compounds. Followed by Nortryptoquivaline (C2), Fiscalin A (C5), Tryptoquival-
ine H (C4), Epi-neofiscalin A (C7), Epi-fiscalin C (C6) and 2,4-Dihydroxy-3-
methylacetophenon (C1) with an IC50 of 123.8 µM, 135.1 µM, 188.3 µM, 144.8 µM 
and 199.2 µM, respectively. Epi-fiscalin A (C8) demonstrated the highest IC50 of all 
compounds (557.0 µM). 
	   	   CHAPTER 3 
 
	   66 
0
5 0
1 0 0
D o x  (0 .5 4 4M )
C 1  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(4 5 % )
****
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l) (3 2 % )
*
A ) C 1
0
5 0
1 0 0
D o x  (0 .5 44M )
C 2  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(4 3 % )
****
(2 2 % )
*
(1 4 % )
*(2 2 % )
**
(4 2 % )
# # # #
(3 2 % )
# # #
(4 5 % )
****
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
B )  C 2
0
5 0
1 0 0
D o x  (0 .5 44M )
C 3  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(4 4 % )
****
(2 5 % )
*
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(4 5 % )
****
(2 4 % )
+ + +
(1 4 % )
+
C ) C 3
0
5 0
1 0 0
D o x  (0 .5 44M )
C 4  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(3 0 % )
*
(3 0 % )
+ + +
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(4 5 % )
****
(2 9 % )
*
(2 2 % )
+ +
D ) C 4
0
5 0
1 0 0
D o x  (0 .5 44M )
C 5  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(3 8 % )
***
(3 1 % )
# #C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(4 5 % )
****
(2 0 % )
+ +
E ) C 5
0
5 0
1 0 0
D o x  (0 .5 44M )
C 6  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(4 1 % )
****
(3 1 % )
# #
(3 4 % )
***
(4 5 % )
****
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(2 0 % )
+ +
F ) C 6
0
5 0
1 0 0
D o x  (0 .5 44M )
C 7  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
(3 4 % )
# #
(4 5 % )
****
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(2 4 % )
+ +
G ) C 7
0
5 0
1 0 0
D o x  (0 .5 44M )
C 8  (4M )
-
-
+ + + + +
- 1 0 5 0 1 0 0
- - -
1
-
1 0 5 0 1 0 01
C
e
ll
 v
ia
b
il
it
y
(%
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
(4 5 % )
****
(2 3 % )
+
(2 0 % )
+ +
H ) C 8
 
 
Figure 4 – Effect of compounds C1 (A), C2 (B), C3 (C), C4 (D), C5 (E), C6 (F), C7 (G), C8 
(H) at 1, 10, 50 and 100 µM alone and in combination with Dox at 0.54 µM on cell viability in 
the A549 cell line. Percentages in brackets refer to a decrease of cell viability in relation to the 
negative control (medium with 0.5% DMSO) or positive control (Dox at 0.54 µM), respectively. 
Results are expressed as mean + SD of at least 3 independent experiments or at least 2 in 
the case of C7 and C8 in combination with Dox at 0.54 µM. Significant differences (*p ≤ 0.05; 
** p ≤ 0.01 and *** p ≤ 0.001) when compared with the negative control and (## p ≤ 0.01 and 
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### p ≤ 0.001) when compared with the positive control were determined by one-way ANOVA 
followed by the post-hoc Newman-Keuls multiple comparison test. Additionally, significant 
differences (+ p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001) when compared with the positive control 
(Dox) were determined by an unpaired Student’s t-test. 
 
3.5. Comparison between the cytotoxic effect of Neosartorya siamensis extract 
and the isolated compounds when in combination with doxorubicin 
 
The comparison of the cytotoxic effect of extract E7 in combination with Dox and 
the compounds (isolated from this extracts) in combination with Dox is represented in 
the Figure 5. The analysis was performed with the concentrations of the compounds 
in combination that demonstrated a cytotoxic effect significantly higher than Dox 
alone (Figure 4), with the intent to comprehend what is the cytotoxic contribute of 
each compound in the effect of the extract of origin (E7) combined with Dox.     
We observed that the combination of C2+Dox (100/0.54) was the most notorious 
result, demonstrating a 22% decrease in cell viability when compared with extract 
E2+Dox (100/0.54). Also, C2+Dox (50/0.54), C5+Dox (100/0.54) and C7+Dox 
(100/0.54) exhibited a significant decrease in cell viability by 11%, 10% and 13%, 
respectively when compared with E7+Dox (100/0.54). None of the remaining combi-
nations revealed significant results (Figure 5). 
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Figure 5 – Comparison between the effect of E7 (100 µg/ml) and the isolated compounds C2, 
C3, C4, C5, C6, C7 and C8 at 50 µM and 100 µM in combination with Dox at 0.54 µM in the 
A549 cell line. Percentages in brackets refer to a decrease of cell viability in relation to the 
extract (E7 at 100 µg/ml + Dox at 0.54 µM). Results are expressed as mean + SD at least 
three independent experiments or at least two in the case of C7 and C8 in combination with 
Dox at 0.54 µM Significant differences (### p ≤ 0.001) when compared with the extract were 
determined by a one-way ANOVA followed by the post-hoc Newman-Keuls multiple compari-
son test. Additionally, significant differences (+ p ≤ 0.05 and) when compared with extract 
were determined by an unpaired Student’s t-test.  
	  
 
4. Discussion  
 
During chemotherapy, cancer cells frequently acquire drug resistance, limiting the 
efficiency of treatment and therapeutical choices for the patient [17]. Doxorubicin is 
an anticancer drug used in the treatment of several types of cancer [18]. Apart from 
several side effects such as cardiac toxicity, drug resistance is a frequent situation 
when doxorubicin therapy is implemented [19]. A strategy to overcome such prob-
lems relies on the implementation of multi-drug combination therapies, which could 
lessen adverse side effects and potentiate the chemotherapeutic drug’s effect [19]. 
In our study we demonstrated, for the first time, that the in vitro anticancer activity 
of doxorubicin could be enhanced by combination with marine-derived fungi extracts 
in lung cancer cells. We also identified some isolated compounds from extract E7 
that could be involved in the potentiation of the cytotoxic effect of doxorubicin. In this 
study, the effect in cell viability of seven crude ethyl extracts derived from Neosar-
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torya tsunodae (E1), Neosartorya laciniosa (E2), Neosartorya fischeri (E3), Aspergil-
lus similanensis (E4), Neosartorya paulistensis (E5), Talaromyces trachsypermus 
(E6) and Neosartorya siamensis (E7) in combination with Dox, was assessed in a 
panel of seven cancer cell lines (HepG2, HCT116, HT29, A549, A375, MCF-7 and 
U251). From the array of extracts and cell lines tested, only extracts E1, E7 and E2 
combined with Dox in A549 cell line showed a significant decrease in cell viability 
when compared with the use of Dox alone. Dox exhibited a potent decrease in cell 
viability in all cell lines. However, the extracts alone possessed low to moderate ef-
fect regarding the decrease of cell viability, with IC50 values ranging from 124 µg/ml 
to > 200 µg/ml µM (data not shown). In A549 cells, only extract E7 alone presented a 
significant decrease in cell viability when compared with the respective control. Inter-
estingly, the extracts that combined with Dox exhibited an enhancement of the de-
crease in cell viability were not those that presented the most appreciable effect in 
cell viability when they are tested alone. Extracts with no significant effect on cell 
viability, namely E1 and E2, when combined with Dox, considerably enhanced the 
effect of Dox alone by 26% and 27%, respectively (Figure 1). While, extract E7 
showed a moderate effect in decreasing cell viability (25%) when used alone, and in 
combination it also enhanced the effect of Dox by 23%. It is possible that extracts E1 
and E2 may be acting to some extent in a mechanism that interferes with doxorubi-
cin’s activity, while extract E7 may act by independent and distinct mechanism of 
Dox. The isolation of compounds from these extracts seems to be of relevance in 
order to precise which compounds are responsible for the demonstrated effects. 
To evaluate possible mechanisms involved on the enhancement of cytotoxic activ-
ity of Dox when in combination with extracts, effects on cell death and DNA damage 
were assessed. Apoptosis is characterized by several hallmarks such as cell shrink-
age, retraction of pseudopods, rounding of the cell, reduction of cellular volume, nu-
clear fragmentation and chromatin condensation. Nuclear condensation is a feature 
that is common to both mitosis and cell death, however, chromatin condensation is 
much more intense in the latter case, and ultimately culminates in nuclear fragmenta-
tion [20,21]. Induction of cell death by assessing nuclear chromatin condensation 
was observed after 48 h exposure to treatments. None of the extracts alone (E1, E7 
and E2) at tested concentrations was able to induce an increase in the number of 
cells with condensed nuclei. This suggests that the extracts alone do not have ability 
to induce cell death. In fact, Dox exhibited an increase in cells with condensed nuclei 
in relation to the negative control. All three extracts combined with Dox (0.54 µM) 
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greatly increased the number of cells with condensed nuclei in comparison to Dox 
(0.54 µM) alone. All combinatory regimens demonstrated the same behavior, by in-
creasing in the number of cells with condensed nuclei when shifting the concentra-
tions from 100 µg/ml to 200 µg/ml of extracts. However the effect on cell viability with 
extracts at 200 µg/ml + Dox at 0.54 µM are not know and should be addressed. 
When extracts are in combination with a low dose of Dox (0.10 µM) none significant 
increase in the nuclear condensation was observed. Several mechanisms of action 
have been proposed for the use of Dox, including DNA intercalation, DNA binding 
and alkylation, DNA cross-linking, interference with helicase activity, inhibition topoi-
somerase II and generation of reactive oxygen species (ROS) [18]. Some studies 
report dose-dependent effect with the use of Dox, suggesting that different mecha-
nism of actions may occur according with the dose of Dox used [22]. Our results 
show that the induction of cell death is dependent of the concentration of Dox, with a 
minimal concentration of Dox below of which no effect is observed independently of 
extract concentration. Since no effect was detected from the use of the extracts 
alone, these observations suggest that the underlying mechanism of cell death is 
tightly associated to a higher dose of Dox, which may trigger a different mechanism 
than when exposing cells to a lower dose of Dox. Additionally, when the higher con-
centration of Dox is combined with the extracts the induction of cell death is greatly 
augmented.  
Several anticancer drugs act by inducing a high level of DNA damage and if the 
repair ability is overcome then induction of apoptotic pathways may be activated and 
in this way eliminating tumors cells. So, induction of DNA damage is often ap-
proached to predict cell death mediated by genotoxic drugs, whose action involves 
the disruption of nuclear DNA [23]. Cell death may indeed occur if the damage oc-
curs in intense way and in fundamental regions of the DNA, with no repair mecha-
nism to lessen their consequence. In this sense, the use of an alkaline comet assay, 
that allows the detection of DNA strand breaks (SB) and alkali-labile sites, could pro-
vide evidence of an early interaction of a chemical agent and the nuclear DNA 
[24,25]. Single-strand breaks (SSB) and double-strand breaks (DSB), are types of 
DNA damage caused by certain anticancer drugs such as Dox [26]. 
In our study, the combination of E7+Dox (200/0.54) and E2+Dox (200/0.54) after 
48 h, demonstrated a significant increment of DNA damage when compared with 
Dox alone. The extract E2 alone at a concentration of 200 µg/ml was the only extract 
that was able induce an increase of 6% in DNA damage by its own, in relation to the 
	   	   CHAPTER 3 
 
	   71 
negative control, but without effect on cell death, maybe because this damage is not 
sufficient to activate the cell death pathways. Extracts E7 and E2 when combined 
with Dox increase DNA damage detected by comet assay. This could be due a de-
crease of DNA repair capacity and/or a decrease of antioxidant defenses with accu-
mulation of DNA damage. Some studies showed that Dox induce DNA damage, 
mainly DSBs, due to it interaction with topoisomerase II and by production of reactive 
oxygen species (ROS) [27]. This damage will activate cell cycle arrest and DNA re-
pair but if they get accumulated apoptosis may be initiated [28]. In our study, none of 
the concentrations of Dox alone were able to induce significant DNA damage in A549 
cell line. This reinforces the issue of drug resistance mechanisms in lung cancer here 
represented by A549 non-small cell lung cancer line [7,3]. In addition, none of the 
combinatory regimens that enhanced cell viability decrease (E+Dox (100/0.54)) in-
duced significant DNA damage when compared with the positive control (Dox at 0.54 
µM). This could suggest that the underlying mechanism associated to the decrease 
of cell viability of these combinations at low concentrations of extracts does not rely 
upon induction of DNA damage (strand breaks). However, for other combinations 
induction of DNA damage may occur.  For a better comprehension of the kinetics of 
DNA damage, a further exposure should be implemented in the attempt to determine 
if DNA damage is increasing or decreasing over time and concentration.  
In the case of extracts E1 and E2, other mechanisms may be involved, for in-
stance, the inactivation of drug transporters (P-gp, LRP, MDR) by allowing the intra-
cellular accumulation of Dox. These hypothesis need confirmation, nonetheless 
seem well corroborated by the total lack of toxicity associated with the use of the 
extracts alone, much like the effect demonstrated by the use of a pump inhibitor 
alone, such as verapamil, in cancer cell lines that when used in combination with 
toxic drugs, the drug’s effect is greatly potentiated [29]. In complement, an activation 
of the p53 tumor suppressor gene by these extracts is also plausible, due to the in-
volvement of p53 on the cytotoxic effect of Dox, namely in A549 cells [30,31]. When 
in combination with Dox, and in a scenario where the p53 gene is functional, cells will 
experience higher rates of cell death, since p53 has an active role in the potentiation 
of pro-apoptotic pathways [31].  
When looking for studies that searched for potential enhancements of the effects 
of established chemotherapeutics by first combining them with extracts, we found 
that an extract from the fucoid algae (200 µg/ml to 400 µg/ml) Cladosiphon navae-
caledoniae was tested in combination with cisplatin (5 µM to 10 µM), tamoxifen (10 
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µM to 20 µM) and paclitaxel (2.5 nM to 5 nM) in two breast cancer cell lines (MDA-
MB-231 and MCF-7) [32]. The authors obtained around 80% of cell growth inhibi-
tion for both cell lines and reported the occurrence of nuclear condensation from 
52% to 66%. Despite these assays and the data cannot be compared directly to 
our scenario, the fact is that herein the decrease in cell viability was around 66%, 
while using a concentration 4-fold lower of the extract and 18 to 37-fold lower con-
centration of the (Dox) chemotherapeutic agent (this when compared to cisplatin 
and tamoxifen). Regarding the induction of nuclear condensation, we reported an 
increase of 23% to 28%, by using a concentration 9 to 19-fold lower of our chemo-
therapeutic agent (in comparison to cisplatin and tamoxifen). In spite of our results 
regarding anticancer activity being slightly less enhanced than the latter study, our 
results point towards an equal trend, suggesting that the extract hold compounds 
that have a potential to be associated with Dox for gains in efficacy at lower doses.  
The overall enhancement of the cytotoxicity of Dox when combined with extracts 
occurs by induction of apoptosis and in some experimental conditions with the induc-
tion of DNA damage. However, other mechanisms such as drug transport, drug me-
tabolism and DNA repair could be involved on the potentiating of cytotoxicity activity 
of Dox in A549 cells and further studies should be equated to address these points. 
Taking in mind the effect of extract E7 on the enhancement of the cytotoxic activi-
ty of Dox in A549 cells, there was a heightened interest in analyzing the eight com-
pounds isolated from this same crude ethyl extract in combination with Dox, in an 
attempt to pinpoint the compound or compounds responsible for the effect observed. 
For this, the eight compounds isolated from the extract E7 were tested alone and in 
combination with Dox and the effect on cell viability was evaluated. The combinatory 
regimens of compounds and doxorubicin demonstrated better results in terms of de-
creasing cell viability, when compared with the use of the compounds alone. Combi-
natory regimens with Dox at 0.54 µM and the compounds chevalone C (C3), tryp-
toquivaline H (C4), fiscalin A (C5), epi-fiscalin C (C6), epi-neofiscalin A (C7) and epi-
fiscalin A (C8) demonstrated a very similar effect amongst themselves, while nortryp-
toquivaline (C2) demonstrated the most prominent effect of all combinations. Overall, 
compound combinations ranged from no effect to 42% more effective than Dox 
alone. Several experiments have tried to formulate drugs based in the combination of 
commercialized drugs or novel compounds with doxorubicin [33,34]. Our results sug-
gest that some of our compounds could be explored with the same purpose.  
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When used alone, some compounds did not exhibit significant results in compari-
son to the positive control, such as C7 and C8. The other compounds tested, when 
alone, were able to decrease cell viability when compared with negative control. In 
some cases, such as compounds C2, C3, C4, C5 and C6, there was a great effect, 
with a decrease in cell viability similar to that observed with Dox at 0.54 µM alone.  
2,4-Dihydroxy-3-methylacetophenone (C1) alone at lowest tested concentration (1 
µM), exhibited a highly significant effect decrease in cell viability when compared with 
the negative control. None of the higher concentrations showed any considerable 
effect, neither did the combination of the compound with Dox (0.54 µM) present any 
additional effect in relation to Dox alone. 
In the study by Buttachon et al., (2012), some of the compounds common to those 
tested in our study were isolated from a terrestrial strain of Neosartorya siamensis 
(KUFC 6349), namely, compounds C1, C4, C5, C7 and C8. Anti-proliferative activity 
of compounds C4 and C8 was assessed in A549 and four other cell lines [16]. The 
IC50 values were reported as being > 100 µM for A549 cell line, which are consistent 
with our own results (Table 1.), replicating and reinforcing the compounds’ potential.   
Additionally, in a study by Sogngam et al., (2014), four compounds that are com-
mon to our compounds C3, C5, C6 and C8 were isolated from the fungus Xylaria 
humosa and their cytotoxic activity was tested in NCI-H187 (small-cell lung cancer) 
and two other cancer cell lines. Compound C3 exhibited a great effect with an IC50 
value of 17.7 µg/ml, while none of the other compounds exhibited an appreciable 
effect [35]. In our study, compound C3 exhibited an IC50 value of 53.8 µg/ml. The IC50 
value of Dox in this cell line was of 0.11 µM. The A549 cell line demonstrated a much 
higher resistance both when exposed to compound C3 and Dox when compared with 
NCI-H187. This may perhaps be explained by differing genotypic profiles between 
the cells. [36, 37].  
In fact, three of the tested compounds (C2, C5 and C7) when in combination with 
Dox exhibited a significant decrease in cell viability greater than the extract E7 in 
combination with Dox. Compound C2 was the most effective by decreasing cell via-
bility 22% more than the extract E7. The remaining two compounds (C5 and C7) 
showed a similar effect by decreasing cell viability in 10 and 13%, respectively, when 
comparing to E7 in combination. These results suggest that compounds C2, C5 and 
C7 could be main players in the effect on cell viability shown by the extract E7. Non
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theless, it was only possible to observe appreciable effects in cell viability reduction 
at higher concentrations (50 µM and 100 µM), with the exception of C1. Compound 
concentrations of 100 µM are equivalent to 40 to 60 µg/ml (depending on the com-
pound), which could be substantially higher than the amount of compound that is 
naturally present in the crude extract. Thus, it is possible that the effect exhibited by 
the extract is a result of combinations of different compounds at lower concentrations 
than those tested. Also, differing compounds than those tested in our study could be 
also contributing for the extract’s activity.  
The results of this study demonstrated that the combination of extracts E1, E7 and 
E2 with doxorubicin showed a more potent an anticancer effect in A549 lung cancer 
cell line, with the increase of cell death mediated mechanisms when compared with 
the use of doxorubicin alone. Three compounds isolated from extract E2 (C2, C5 and 
C7) in combination with doxorubicin demonstrated to have a higher effect in the de-
crease of cell viability when opposed to the use of E7 in combination with doxorubi-
cin. The interest upon the implementation of drug combinations with our extracts and 
compounds in A549 was validated. Further studies must endorse the evaluation of 
potential cellular and molecular targets involved in the cell death mechanism here 
demonstrated. Also, combinations with other commonly used anticancer drugs should 
be thought to offer broader in depth views of the extracts and compounds’ potential. 
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4.1. Conclusions and future perspectives 
 
The first phase of this study aimed the assessment of the in vitro anticancer bioactivity 
of crude ethyl extracts obtained from marine and soil-derived fungi Neosartorya tsunodae 
KUFC 9213, Neosartorya laciniosa KUFC 7896 and Neosartorya fischeri KUFC 6344, in a 
panel of seven cancer cell lines, in particular, in non-small-cell lung carcinoma (A549), 
malignant melanoma (A375), breast adenocarcinoma (MCF-7), colon carcinoma (HT29, 
HCT116), hepatocellular carcinoma (HepG2) and glioblastoma (U251) cells.  
The extracts of N. laciniosa and N. fischeri presented in vitro anticancer activity by de-
creasing cell proliferation, clonogenic potential and increasing both DNA damage and cell 
death associated events (nuclear condensation and morphological alterations) in breast 
adenocarcinoma, malignant melanoma and both colon carcinoma cell lines.  
The second phase had as an objective to evaluate whether a combination of doxorubi-
cin with the crude ethyl extracts obtained from Neosartorya tsunodae KUFC 9213, Ne-
osartorya siamensis KUFA 0017, Neosartorya laciniosa KUFC 7896, Aspergillus similan-
ensis KUFA 0013, Neosartorya paulistensis KUFC 7894, Talaromyces trachsypermus 
KUFC 0021 and Neosartorya fischeri KUFC 6344 as well as with eight compounds isolat-
ed from Neosartorya siamensis KUFA 0017 enhanced doxorubicin’s effect on cell viability. 
The eight isolated compounds were, respectively, 2,4-dihydroxy-3-methylacetophenone 
(C1), nortryptoquivaline (C2), chevalone C (C3), tryptoquivaline H (C4), fiscalin A (C5), 
epi-fiscalin C (C6), epi-neofiscalin A (C7) and epi-fiscalin A (C8).  
The enhancement of doxorubicin’s anticancer activity was indeed achieved when used 
in combination with extracts from N. tsunodae, N. siamensis, N. laciniosa in the A549 lung 
cancer cell line. The combinations of doxorubicin and extracts demonstrated a significant 
decrease in cell viability, and an increase in DNA damage and in cell death associated 
events (nuclear condensation and morphological alterations).  
The promising results obtained with the combination of doxorubicin and N. siamensis 
extract in the A549 cells encouraged the evaluation of the effect on cell viability of com-
pounds C1 to C8, in combination with doxorubicin in the same cell line. Although these 
compounds are not novel isolates, having also been isolated from other fungi of terrestrial 
origin, and concomitantly screened for anti-proliferative activity in a few cancer cell lines, 
to our knowledge, it is the first time that these compounds were evaluated in a combinato-
ry regimen for the enhancement of the anticancer activity of doxorubicin in a lung cancer 
cell line. Results demonstrated that all (C2 to C8) but one compound (C1) exhibited an 
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enhancement of the doxorubicin effect in the decrease of cell viability in A549. In particu-
lar, compounds C2, C5 and C7 displayed a more significant decrease in A549 cell viability 
than the exhibited by the use of extract from N. siamensis in combination with doxorubicin.  
Moreover, the overall results obtained with this screening suggest that compounds C2, 
C5 and C7 may in fact be the compounds responsible for the anticancer effect observed 
with the N. siamensis extract in the A549 lung cancer cell line.  
Future approaches that should be followed in the sequence of this study should involve 
the better understanding of the extent of the effectiveness of the combinatorial regimens 
of extracts and doxorubicin / compounds and doxorubicin. 
In our view, there is particular interest in the isolation and anticancer screening, and in 
getting further mechanistic insights, of compounds from the extracts that presented signif-
icant enhancement of doxorubicin’s activity, namely those derived from N. tsunodae and 
N. laciniosa. In particular for N. tsunodae, which demonstrated no cytotoxic effect when 
used alone, while in combination with doxorubicin demonstrated a high cytotoxic effect. 
A greater range of extract/compound concentrations must be tested in order to calcu-
late the combinatory index (CI), which will effectively determine whether the combination 
is of synergistic, additive or antagonistic nature.  
The combination of doxorubicin and compounds must also be subjected to assessment 
of DNA damage and induction of cell death by apoptosis. The analysis of apoptotic in-
volvement should include assays for several apoptotic features, for example, assessing 
mitochondrial membrane potential, measurement of caspase activity, DNA fragmentation, 
phosphatidylserine (PS) externalization and morphological alterations by electron micros-
copy. The analysis of cell cycle arrest should also be ensued. 
Having identified the pathway of cell death, further studies should be pursued in order 
to understand the specific interaction between the extracts/compounds and doxorubicin, 
as for example, assessing the accumulation of doxorubicin in the cells and P-glycoprotein 
expression. More importantly, considering that lung cancer is highly resistant to chemo-
therapy, the expression of the lung resistance-related protein (LRP) should be evaluated.  
Additionally, other combinations with other chemotherapeutic drugs should be evaluat-
ed, in an effort to find more potential combinatory enhancement. Drugs that are commonly 
used in the treatment of lung cancer are of critical interest. Other lung cancer cell lines 
should also be used, in order to unravel possible differentiation between distinct lung can-
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cer genetic profiles. Inclusively, testing these combinations on multi-drug resistant (MDR) 
cell lines may also be a preferable path for getting new perspectives in further studies.  
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P1. CELL CULTURE 
 
Principle 
 
Cell culture is based on the maintenance of disassociated cells in vitro, and in the case of cancer 
cells, these cells may be developed from primary cultures obtained from tumours, and may prolif-
erate indefinitely in culture as cell lines. Cultured cells must be grown in a favorable artificial envi-
ronment with the monitoring of physicochemical (e.g. temperature, pH, O2 and CO2 tension) and 
physiological conditions (e.g., nutrients and growth factors). General cell maintenance also ensures 
that cell lines that grow in monolayer are sub-cultured into new flasks upon reaching 80-90% con-
fluence by using enzymatic dissociation (e.g. trypsin). When an experimental assay is to take 
place, it is vital to ensure the continuity of the cell line by sub-culturing, and subsequently proceed-
ing to the calculus of cell viability and density for the preparation of cell suspension at the desired 
density (Langdon, 2004; Freshney, 2010). 
 
 
Materials Assay solutions and reagents 
T25 or T75 cell culture flasks 
Humidified CO2 incubator 
Inverted contrast phase microscope 
Laminar flow chamber 
Neubauer chamber 
 
 
PBS (Phosphate Buffered Saline) buffer 
0.25% Trypsin/EDTA solution 
Cell culture medium (MEM, DMEM and RPMI) 
Fetal Bovine Serum (FBS) 
HEPES 
Sodium bicarbonate 
Sodium pyruvate 
Penicillin and Streptomycin (Antibiotics) 
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CELL CULTURE MAINTENANCE AND MANIPULATION 2 
 
Starting a new cell culture 
1. When starting a fresh culture of cells, use an aliquot of cells preserved in a liquid 
nitrogen cell container. Prefer aliquots with a smaller passage number. 
2. Quickly thaw the cells, placing all the content of the aliquot into a sterile culture 
flask, with 4 ml of cell culture medium at 37ºC.  This procedure avoids toxicity from 
the DMSO in the freezing medium. 
3. Shake the flask with care to evenly spread the cell solution. 
4. Incubate the cells in a humidified incubator at 37ºC and 5% CO2. 
5. Do not move the flasks during the 24 h incubation period. 
6. After adhered, change the medium to remove remains of DMSO.  
 
Changing cell medium 
1. Every two days, change the medium of cultured flasks.  
2. Before starting the procedure, be sure to examine for confluence, dead cells and 
contamination under an inverted contrast phase microscope. 
3. Heat PBS and cell culture medium to 37ºC in an appropriate and uncontaminated 
water bath. 
4. In the laminar flow chamber, carefully remove the medium from the flask. 
5. Wash the bottom of the flask with 1 ml of PBS to remove debris, this point may be 
repeated as desired. Remove the PBS. 
6. Add 5 ml of appropriate cell culture medium. 
7. Incubate cells in a humidified incubator at 37ºC and 5% CO2. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 All protocols involving cell maintenance and manipulation must be done under sterile conditions. The use of 
a laminar flow chamber and aseptic techniques is essential.  
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Sub-culturing 
1. Cells will generally need to be sub-cultured once a week or when a confluence > 
80% is reached. 
2. Heat a trypsin/EDTA solution to 37ºC in an appropriate and uncontaminated water 
bath. It is preferable to have the medium and PBS at room temperature. 
3. Remove the medium from the flask with care. 
4. Wash the cells twice with 1 ml of PBS and remove after washing. 
5. Add 1 ml of trypsin/EDTA solution and incubate for 5 min at 37ºC. 
6. Observed under an inverted contrast phase microscope for detached and rounded 
cells. 
7. When cells become detached add 4 ml of medium and slowly resuspend. Note: 
Could be necessary to resuspend cells before adding the medium if the cells form 
large aggregates. 
8. Remove a certain amount of cell suspension, in accordance with cell proliferation 
speed, e.g. sub-culturing ratio of 1:8. 
9. Add medium up to 5 ml and spread the cell suspension evenly.  
10.  Incubate in a humidified incubator at 37ºC and 5% CO2.  
 
 
References 
 
Freshney, R. I. (2010) Subculture and Cell Lines, in Culture of Animal Cells: A Manual of Basic 
Technique and Specialized Applications, Sixth Edition, John Wiley & Sons, Inc., Hoboken, 
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Langdon, S. P. (2004). Introduction to Cancer Cell Culture in Cancer Cell Culture: Methods and 
Protocols (Vol. 88): Springer. 
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P2. MTT ASSAY	  
 
 
Principle 
 
The MTT colorimetric assay allows the evaluation of the effects of a test compound on cell 
viability and cell proliferation (Vega and Pugsley, 2011). This assay corresponds to a sim-
ple and quick way to assess the cytotoxic or preventive effect of a particular substance in 
a designated cell line. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
is a water soluble tetrazolium salt that in viable cells is converted by mitochondrial path-
ways to formazan crystals, which are water insoluble and can be quantified by optical 
density (O.D) using a microplate reader at a wavelength of 570 nm. The amount of forma-
zan crystals will be directly proportional to the amount of viable cells (Plumb, 2004).    
 
 
 
Materials Assay solutions and reagents 
96-multiwell culture plates PBS  (Phosphate Buffered Saline) buffer 
Microplate reader (570 nm) MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) 
 Solubilization solution – DMSO:Ethanol (1:1)  
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Assay solution preparation 
 
I .  1X PBS (Phosphate Buffered Saline) buffer 
 Final concentration Weight 
   
NaCl 137.0 mM 8.0 g 
KCl 2.7 mM 0.20 g 
Na2PO4 10.0 mM 1.44 g 
KH2PO4 2.0 mM 0.24 g 
 
Weight all reagents and add 800 ml of ultrapure H2O. Subsequently, adjust pH to 7.4 by using HCl 
or NaOH solution as necessary. After adjusting the pH, add H2O to a final volume of 1 L. Sterilize 
the solution by autoclaving and store at 4ºC. 
 
I I .  MTT stock solution (5 mg/ml) 
 Final concentration Weight 
MTT 5 mg/ml 50 mg 
 
Dissolve 50 mg of MTT in 10 ml of PBS. Dissolve by the use of an ultrasound bath. Solution is 
aliquot as desired and store at -20ºC until use. 
 
I I I .  Solubilization solution – DMSO: Ethanol (1:1) 
To obtain 500 ml of solubilization solution, add 250 ml of DMSO and 250 ml of absolute ethanol. 
Use a fume hood to avoid contact with toxic vapors. Store the solution protected from light at room 
temperature. 
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Assay procedure 
 
Cell metabolization of formazan crystals 
1. Work under aseptic conditions by using a laminar flow hood. 
2. Incubate cells in a 96-multiwell culture plate with a final volume of 100 µl/well and 
a cellular density appropriate for each cell line (according with experimental de-
sign). Leave cells to adhere for 24 hours at 37ºC in the incubator.  
3. Apply the desired treatment (according to experimental design). At this time add 10 
µl of MTT 3 (0.5 µg/ml) to the initial control (Ci). Incubate the plate for two hours at 
37ºC and 5% CO2. 
4. After incubation, remove the medium from the Ci without removing the crystals, 
which should be adhered to the bottom of the well. 
5. Place the culture plate in the incubator, and let incubate for the remaining 46 h. 
6. At the end of the treatment, add 10 µl of MTT (0.5 µg/ml) per well and incubate for 
two hours at 37ºC and 5% CO2 4. Afterwards, remove the medium.  
7. Add 150 µl of the solubilization solution (DMSO:Ethanol) 5 to each well. 
8. Shake the plate gently for 10 min until a homogenous solution is obtained. 
9. Read the optical density of the solution at a wavelength of 570 nm in a microplate 
reader. If possible, just before reading gently shake the plate.  
10. The percentage of cell proliferation and cellular inhibition must be calculated by 
equations 1 and 2, respectively. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 MTT is highly toxic and carcinogenic, it must be disposed to a toxic waste container and never be mixed with 
normal waste. Handle with care. 
4 Due to the photosensitivity of the formazan crystals, from this point forward protect the plate from light. The 
following points do not require the use of a laminar flow hood. 
5 DMSO is toxic and highly volatile. Use the fume hood and handle with care. 
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Calculation of cell proliferation and IC50 
The half maximal inhibitory concentration (IC50) can be calculated using dose-response 
analysis performed in appropriate statistical software.  
The percentage of cell proliferation may be calculated according to the equation 1 6:  
 
(1)  % of cell proliferation = (ODsample – OD t=0 h) / (OD t=48 h – OD t=0 h) x 100. 
 
The percentage of cell inhibition may be calculated according to the equation 2:  
(2)    % of cell inhibition = 100 - % of cell proliferation. 
 
 
 
References 
 
Plumb, J. A. (2004). Cell sensitivity assays: the MTT assay Cancer Cell Culture (pp. 165-169): 
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growth and viability Drug Design and Discovery (pp. 157-168): Springer. 
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Western Pharmacology Society. 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 OD corresponds to optical density 
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P3. NUCLEAR CONDENSATION 
 
  
Principle 
Apoptosis is characterized by several hallmarks such as cell shrinkage, retraction of 
pseudopods, rounding of the cell, reduction of cellular volume, nuclear fragmentation and 
chromatin condensation (Wong, 2011). Nuclear condensation is a feature that is common 
to both mitosis and cell death, however, chromatin condensation is much more intense in 
the latter case, and ultimately culminates in nuclear fragmentation. The observation of this 
phenomenon is possible after appropriate cell isolation and fixation, with the staining of 
nuclear DNA with an adequate fluorochrome and observation under a fluorescence micro-
scope. DAPI (4',6-diamidino-2-phenylindole) is a fluorochrome that binds with the A-T 
regions of the DNA and is consequently commonly used as a stain when assessing nu-
clear condensation (Toné, Sugimoto, et al., 2007). 
 
 
 
Materials Assay solutions and reagents 
96-multiwell culture plates  
Centrifuge 
Cytocentrifuge 
Hydrophobic barrier pen 
Poly-L-Lysine microscope slides 
Fluorescence microscope 
 PBS (Phosphate Buffered Saline) buffer 
0.25% Trypsin/EDTA solution 
DAPI staining solution (1 µg/ml) 
50% Glycerol solution 
4% Paraformaldehyde (PFA) (w/v) 
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Assay solution preparation 
 
 
I .  1X PBS (Phosphate Buffered Saline) buffer 
 Final concentration Weight 
   
NaCl 137.0 mM 8.0 g 
KCl 2.7 mM 0.20 g 
Na2PO4 10.0 mM 1.44 g 
KH2PO4 2.0 mM 0.24 g 
 
Weight all reagents and add 800 ml of ultrapure H2O. Subsequently, adjust pH to 7.4 by using HCl 
or NaOH solution. After adjusting the pH, add H2O to a final volume of 1 L. Sterilize the solution by 
autoclaving and store at 4ºC. 
 
II. DAPI staining solution (1 µg/ml) 
From a DAPI stock solution of 100 µg/ml, prepare a 1 µg/ml working solution in ultrapure H2O. Pro-
tect from light and store at -20ºC. 
 
III. 50% Glycerol solution (v/v) 
To prepare 10 ml of glycerol solution, mix 5 ml of glycerol and 5 ml of PBS (1X). 
 
IV. 4% Paraformaldehyde (PFA) (w/v) 
 Final concentration Weight 
Paraformaldehyde (PFA) 4% 4 g 
 
For a 100 ml solution, weight 4 g of PFA and add PBS (1X) until reaching 100 ml. Heat the solution 
in a water bath at 60ºC and stir frequently. This solution will take several hours until totally dis-
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solved. Allow the solution to cool at room temperature and fix the pH to 7.4. Store at -20ºC until use 
7.  
 
 
Assay procedure 
 
Sample preparation 
1. Incubate cells in a 24-multiwell culture plate with a final volume of 1000 µl/well and 
a cellular density appropriate for each cell line (according to experimental design), 
e.g. 0.1x106 cells/ml.  
2. Leave cells to adhere for 24 hours in the incubator at 37ºC and 5% CO2.  
3. Apply the desired treatment and leave to incubate for 48 hours (according to ex-
perimental design). 
4. After the end of the treatment, collect the medium from each well and place in a 
respectively labeled centrifuge tube.  
5. Wash each well with 1 ml of PBS (1X) and collect to the respective centrifuge tube. 
6. Trypsinize each well with 150 µl of warm trypsin/EDTA solution and incubate at 
37ºC and 5% CO2 for about 5 min.  
7. Stop the trypsinization process in each well by adding 400 µl of the respective pre-
viously collected medium. Resuspend the cells carefully. 
8. Wash each well with 1ml of PBS (1X) and add to the respective centrifuge tube. 
9. Centrifuge the tubes for 10 min at 2000 rpm.  
10. Save 500 µl of the solution, and discard the remaining supernatant without disrupt-
ing the pellet.  
11. Add 3 ml of PBS (1X) to the reserved 500 µl, and carefully resuspend. 
12. Centrifuge the falcons for 10 min at 2000 rpm. 
13. Save 500 µl of the supernatant and discard the remaining. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Keep the solution in a well-sealed recipient it releases toxic vapors when heated  
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14. Resuspend the pellet in the 500 µl of supernatant.  
15. Add 2 ml of 4 % paraformaldehyde solution and leave to incubate for at least 15 
minutes at 37ºC. 
16. Add 4 ml of PBS (1X) to each sample.  
17. Centrifuge again at 2000 rpm for 10 min and repeat the steps 13 and 14. 
18. Collect the sample into a respectively marked tube. 
19. Store the samples at 4ºC. Samples will remain stable under these conditions for 
several months. 
 
Nuclear staining 
1. Identify poly-L-Lysine slides and mount into the appropriate cytocentrifuge frames. 
Poly-L-Lysine coated slides are advisable to ensure that cells attach to the slide 
during the cytocentrifugation. 
2. Resuspend each sample and pipette around 80 µl - 120 µl of cell suspension into 
the cytocentrifuge tube 8.  
3. Centrifuge the slides in a cytocentrifuge for 5 min at 500 rpm. 
4. Unmount the slides carefully, making sure that the cells are adhered to the slide. At 
this stage you can verify if the volume of cells used is appropriated. 
5. Circle the adherent cells with a hydrophobic barrier pen, and leave to air dry for 10-
20 min. 
6. Wash 3 times with PBS (1X) for 5 min.  
7. Incubate with DAPI (1 µg/ml) for 10 minutes in the dark 9. 
8. Add 6 µl of 50% glycerol solution to each sample, and place a coverslip. 
9. Place the samples at – 20ºC and protected from light. Samples can be preserved 
at this temperature for several months. Alternatively, observe the sample immedi-
ately by using a fluorescence microscope.   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 The volume used must take in account cellular density. High density will make visualization difficult. Low 
density could make the quantification of 300 nuclei impractical. 
9 DAPI is carcinogenic. Handle with care. 
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Visualization and quantification 
Observe samples in a fluorescence microscope and keep the room with the lowest light 
conditions as possible. Stained nuclei will appear with a blue coloration. The correct quan-
tification of nuclear condensation requires a clear distinction between this event and other 
physical structures such as debris, damaged nuclei, among others that may resemble a 
result of nuclear condensation. The above-mentioned situations must never be quantified 
as nuclear condensation. The visualization of nuclear condensation does not appear as a 
standardized image, yet one must consider that an array of slightly altered situations will 
correspond to a positive count of nuclear condensation.  
Quantification of nuclear condensation is obtained by counting at least 300 cells with con-
densed nuclei. The percentage of nuclear condensation is calculated by applying the fol-
lowing equation:  
% of cells with condensed nuclei = (number of cells with condensed nuclei / total num-
ber of cells counted) x 100 
 
At least 3 independent experiments must be done. It is advisable that the same research-
er is responsible for all the visual quantification of the whole group of experiments, so that 
the same criteria will be maintained. 
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P4. COMET ASSAY 
 
Principle 
 
The single cell gel electrophoresis assay or “comet assay” is a method for measuring DNA 
damage in single cells. The principle of the assay consists on the migration of the 
loops/fragments of DNA through an agarose gel when submitted to an electric field.  This 
assay includes several steps, such as obtaining of isolated cells, mixing with agarose, 
cellular lysis, alkaline treatment (DNA unwinding), electrophoresis (DNA migration), stain-
ing with DNA-specific fluorescent dyes and microscope analysis. The alkaline version of 
the comet assay (the pH of the alkaline treatment is more than 13) allows the detection of 
DNA strand breaks and alkali labile sites. The presence of strand breaks relaxed super-
coiled DNA allowing the migration of the DNA loops giving an image like a comet in sky. 
The use of a fluorescence microscope to capture and visualize and appropriate software 
for imaging analysis (e.g. CometScore®) will give information on the % of DNA damage 
through the % of DNA in the comet tail. DNA migration is directly proportional to DNA 
damage (Collins, 2004; Olive and Banáth, 2006; Collins, Oscoz et al., 2008). 
 
 
Materials Assay solutions and reagents 
24-multiwell culture plates 
Horizontal electrophoresis tank 
Electric power supply 
Microscope slides 
Fluorescence microscope 
 
PBS (Phosphate Buffered Saline) buffer 
0.25% Trypsin/EDTA solution 
DAPI staining solution (1 µg/ml) 
1% Normal Melting Point Agarose (NMP) (w/v) 
0.5% Low Melting Point Agarose (LMP) (w/v) 
Lysis solution, pH 10 
Electrophoresis Buffer 
Absolute ethanol 
 
	   	   APPENDIX 
	  
102	  
Assay solution preparation 
 
I. 1X PBS (Phosphate Buffered Saline) buffer 
 Final concentration Weight 
   
NaCl 137.0 mM 8.0 g 
KCl 2.7 mM 0.20 g 
Na2PO4 10.0 mM 1.44 g 
KH2PO4 2.0 mM 0.24 g 
 
Weight all reagents and add 800 ml of ultrapure H2O. Subsequently, adjust pH to 7.4 by using HCl 
or NaOH solution. After adjusting the pH, add H2O to a final volume of 1 L. Sterilize the solution by 
autoclaving and store at 4ºC. 
 
II. 1% Normal Melting Point Agarose (NMP) (w/v) 
Prepare a solution with 200 mg of normal melting point agarose (NMP) and distilled water until 20 
ml. To dissolve the solution, heat in a microwave at full power for 1 to 2 min. Store the solution at 
4ºC. When required, melt the solution before use. 
 
III. 0.5% Low Melting Point Agarose (LMP) (w/v) 
Prepare a solution with 100 mg of low melting point agarose (NMP) and PBS (1X) until 20 ml. To 
dissolve the solution, heat in a microwave at full power for 1 to 2 min. Store the solution in 2 ml 
aliquots at 4ºC. When required, melt the solution before use. 
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IV. Lysis solution, pH 10 
 Final concentration Weight 
   
NaCl 2.5 M 146.1 g 
Na2EDTA 100.0 mM 37.2 g 
Tris Base 10.0 mM 1.21 g 
NaOH to pH of 10  Approx. 7 g 
 
 
For 1 L of solution add 146.1 g of NaCl, 37.22 g of Na2EDTA, 1.211 g of Tris Base and around 5 g 
of NaOH (save ~2 g for further use). Add distilled water until reaching the 900 ml and stir the solu-
tion. The remaining 2 g will have to be gradually added to the solution as the dissolution occurs 
and until reaching the correct pH. When totally dissolved add the remaining volume of distilled wa-
ter up to a volume of 1 ml. Store the solution at 4ºC. Add triton X-100 1% (v/v) immediately prior to 
use. 
 
V. Electrophoresis Buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13) 
 Final concentration Weight 
NaOH 3 M 120 g 
 
Add NaOH and distilled water until reaching 1 L. Dissolve and store at 4ºC. 
 
Na2EDTA 200 mM 3.722 g 
 
Add distilled water until reaching 50 ml. Dissolve and store at 4ºC. 
Mix only both solutions immediately prior to use. For 1 L of electrophoresis buffer use 100 ml of 3M 
NaOH, 5 ml of 200 mM Na2EDTA and 895 ml of distilled water. The pH of this solution should be ≥ 
13. Wear protective gloves and handle with care. 
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VI. DAPI staining solution (1 µg/ml) 
 
From a DAPI stock solution of 100 µg/ml, prepare a 1 µg/ml working solution in ultrapure H2O. Pro-
tect from light and store at -20ºC. 
 
 
Assay procedure 
 
The elaboration of this protocol will require an anticipated preparation of the material and 
reagents mentioned in the “Assay solutions and reagents/Materials” section. A thoughtful 
reading of this section is mandatory. 
 
Slide preparation 
Coat one side of a conventional microscope slide dipping the slide in melted 1% NMP 
agarose (w/v) solution. Place horizontally and leave to air dry at room temperature for 10 
min. Then place the slides overnight at 37ºC to dry completely. 
 
Cell preparation  
1. Incubate cells in a 24 multi-well plate with a final volume of 1000 µl/well and a cel-
lular density appropriate for each cell line (according to the desired experimental 
design), e.g. 0.1x106 cells/ml.  Leave cells to adhere for 24 hours in the incubator 
at 37ºC and 5% CO2.  
2. Apply the desired treatment and expose cells for 4, 24 and 48 hours (according to 
the experimental design). 
3. After reaching the end of the treatment, remove the medium from each well and 
wash twice with 200 µl of PBS (1X). 
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4. Trypsinize each well with 100 µl of trypsin/EDTA solution and incubate at 37ºC and 
5% CO2 for about 5 min. 
5. Stop the trypsin action by adding 400 µl of cold medium to each well and resus-
pend. 
6. Count the cells and prepare a cell suspension (5x104 cells/ml) for each sample. 
From here on, keep the cells on ice to prevent the activation of DNA damage re-
pair mechanisms. 
7. Centrifuge cells for 1 min at 5,000 rpm. If the volume of cells is lower than 10 µl, 
this step is unnecessary. 
8. Remove the supernatant, and add 100 µl of LMP agarose and resuspend each 
sample. LMP agarose must be melted before using (melting point ~60ºC) be sure 
to cool down to 37ºC in a water bath as to not damage the cells. 
9. Apply ~75 µl of the cell suspension (cells plus LMP agarose) to the slide and place 
a coverslip over it. One slide is suitable for two samples. Keep the slides at 4ºC 
around 5 to 10 min. 
10. When the LMP agarose in the slides is solidified (~ 10 min at 4ºC), remove the co-
verslips with care, to avoid damaging the gel. 
11. Fully immerse the slides in the lysis solution. 
12. Incubate for 2 hours at 4ºC in the dark. Possible stop point - if necessary leave 
overnight. 
13. Pour the electrophoresis buffer solution into the electrophoresis tank and maintain 
at 4ºC. 
14. After incubation, rinse the slides with distilled water and place them in the electro-
phoresis tank. 
15. Incubate the slides for 40 minutes in electrophoresis buffer at 4ºC to unwind the 
DNA. Place the label in the direction of the anode. 
16. Run the electrophoresis at 20 V (1V/cm) for 20 minutes at 4ºC. 
17. Remove slides from the tank and wash 3 times in distilled water for 5 minutes 
each. Be careful not to damage the gel on the slides. 
18. Dehydrate the slides by immersing them twice for 5 minutes in absolute ethanol. 
Leave to air dry. 
19. Stain each sample with 20 µl of DAPI (1 µg/ml). 
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20. Samples may now be observed under a fluorescence microscope. 
 
Evaluation of DNA damage 
DNA damage evaluation is assessed by fluorescence microscopy using a 20X or a 40X 
objective. Avoid cells in the gel borders and make sure that you are not capturing the 
same area repeatedly.  
Capture at least 100 cells per sample, and process the image by using comet analysis 
software, such as CometScore®. Express the results as percentage of DNA in the tail, 
additional results may be expressed as tail moment or tail length. 
 
References 
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P5. CLONOGENIC ASSAY 
 
 
Principle 
 
The clonogenic or colony forming assay is a cell survival assay based which is used to 
analyse indefinite cell proliferation. This assay determines whether a single cell previously 
exposed to a desired toxic agent maintains a long-term ability to form a colony. Results 
obtained from this experiment allow the understanding of whether the toxic agent used 
possesses cytostatic activity by altering the cell’s reproductive viability (Franken, Roder-
mond et al. 2006; Haloom, Christian et al. 2011). 
 
 
 
Materials Assay solutions and reagents 
24-multiwell culture plates 
12-multiwell culture plates 
Stereomicroscope 
Laminar flow hood 
 
PBS (Phosphate Buffered Saline) buffer 
0.25% Trypsin/EDTA solution 
4% Paraformaldehyde (PFA) (w/v) 
0.05% Crystal violet (w/v) 
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Assay solution preparation 
 
I. 1X PBS (Phosphate Buffered Saline) buffer 
 Final concentration Weight 
   
NaCl 137.0 mM 8 .00g 
KCl 2.7 mM 0.20 g 
Na2PO4 10.0 mM 1.44 g 
KH2PO4 2.0 mM 0.24 g 
 
Weight all reagents and add 800 ml of ultrapure H2O. Subsequently, adjust pH to 7.4 by using HCl 
or NaOH solution. After adjusting the pH, add H2O to a final volume of 1 L. Sterilize the solution by 
autoclaving and store at 4ºC. 
 
 
I I .  4% Paraformaldehyde (w/v)  
 Final concentration Weight 
Paraformaldehyde (PFA) 4% 4 g 
 
For a 100 ml solution, weigh 4 g of PFA and add PBS (1X) until reaching 100 ml. Heat a water bath 
at 60ºC and stir it frequently, this solution will take several hours until become total dissolved (keep 
the solution in a well-sealed recipient because it releases toxic vapors when heated). Wait until it 
settles at room temperature and fix pH=7.4. Store at -20ºC until use.  
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I I I .  0.05% Crystal violet (w/v) 
 Final concentration Weight 
Crystal violet 0.05% 5 mg 
 
Add 5 mg of crystal violet and add up to 100 ml with PBS (1X).  
 
 
Assay procedure 
 
 Cell preparation 
1. Incubate cells in a 24 multi-well plate with a final volume of 1000 µl/well and a cel-
lular density appropriate for each cell line (according to the desired experimental 
design), e.g. 0.1x106 cells/ml.   
2. Leave cells to adhere for 24 hours in the incubator at 37ºC and 5% CO2.  
3. Apply the desired treatment and expose cells for 48 hours (according to the exper-
imental design). 
4. After reaching the end of the treatment, remove the medium from each well and 
wash twice with 200 µl of PBS (1X). 
5. Trypsinize each well with 100 µl of trypsin/EDTA solution and incubate at 37ºC and 
5% CO2 for about 5 min. 
6. Stop the trypsin action by adding 400 µl of cold medium to each well and resus-
pend. 
7. Count the cells and prepare serial dilutions to prepare a final cell suspension of 
200 cells in 1 ml for each sample. Resuspend every dilution with care, to ensure 
that the final solution contains the right amount of cells.  
8. Plate the cell suspension of 1 ml containing 200 cells in a 12-multiwell culture 
plate. 
9. Leave cells to incubate for 10 days in the humidified incubator at 37ºC and 5% 
CO2.  
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10.  At the end of the incubation period, remove the medium and was with 2 ml of 
warm PBS. 
11.  Cells must then be fixed in situ with 2 ml of 4% paraformaldehyde and left to incu-
bate for 15 min at 37ºC. 
12.  Remove the paraformaldehyde and wash with 2 ml of warm PBS.  
13.  Remove the PBS and add 2 ml of 0.05% crystal violet dye, and leave to incubate 
for 30 min at room temperature. 
14.  Remove the crystal violet and wash with distilled water. Be careful as to not lift the 
cells. 
15.  Leave to air-dry overnight. 
16.  The plate is now ready to be examined. Under a stereomicroscope, count cell col-
onies with more than 50 cells. 
 
Calculations 
With the data obtained it is possible to calculate the plating efficiency through the ratio of 
the number of colonies with more than 50 cells and the number of cells plated. As a con-
sequence, the surviving fraction in relation to the negative control is calculated according 
to the following equation: 
% Surviving fraction (SF) = (PE treated cells / PE control) x 100 
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